BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: KDOQI. ; National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006;47:S11-145. [PMID: 16678659 DOI: 10.1053/j.ajkd.2006.03.010] [Cited by in Crossref: 187] [Cited by in F6Publishing: 295] [Article Influence: 11.7] [Reference Citation Analysis]
Number Citing Articles
1 Locatelli F, Reigner B. C.E.R.A.: pharmacodynamics, pharmacokinetics and efficacy in patients with chronic kidney disease. Expert Opinion on Investigational Drugs 2007;16:1649-61. [DOI: 10.1517/13543784.16.10.1649] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
2 Rahman A, Yamazaki D, Sufiun A, Kitada K, Hitomi H, Nakano D, Nishiyama A. A novel approach to adenine-induced chronic kidney disease associated anemia in rodents. PLoS One 2018;13:e0192531. [PMID: 29415057 DOI: 10.1371/journal.pone.0192531] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
3 Foley RN, Zhang R, Gilbertson DT, Dunning S, Ishani A, Collins AJ. Exceeding hemoglobin target levels in US hemodialysis patients receiving epoetin, 1999 to 2002. Hemodialysis Int 2007;11:333-9. [DOI: 10.1111/j.1542-4758.2007.00189.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
4 David V, Martin A, Isakova T, Spaulding C, Qi L, Ramirez V, Zumbrennen-Bullough KB, Sun CC, Lin HY, Babitt JL, Wolf M. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int 2016;89:135-46. [PMID: 26535997 DOI: 10.1038/ki.2015.290] [Cited by in Crossref: 240] [Cited by in F6Publishing: 209] [Article Influence: 40.0] [Reference Citation Analysis]
5 Warady BA, Silverstein DM. Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease. Pediatr Nephrol 2014;29:1493-505. [PMID: 24005791 DOI: 10.1007/s00467-013-2557-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
6 Jasti DB, Mallipeddi S, Apparao A, Vengamma B, Sivakumar V, Kolli S. A Clinical and Electrophysiological Study of Peripheral Neuropathies in Predialysis Chronic Kidney Disease Patients and Relation of Severity of Peripheral Neuropathy with Degree of Renal Failure. J Neurosci Rural Pract 2017;8:516-24. [PMID: 29204008 DOI: 10.4103/jnrp.jnrp_186_17] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
7 Adibe MO, Ewelum PC, Amorha KC. Evaluation of drug-drug interactions among patients with chronic kidney disease in a South-Eastern Nigeria tertiary hospital: a retrospective study. Pan Afr Med J 2017;28:199. [PMID: 29610637 DOI: 10.11604/pamj.2017.28.199.13622] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Yu PH, Lin MY, Chiu YW, Lee JJ, Hwang SJ, Hung CC, Chen HC. Low serum iron is associated with anemia in CKD stage 1-4 patients with normal transferrin saturations. Sci Rep 2021;11:8343. [PMID: 33863963 DOI: 10.1038/s41598-021-87401-w] [Reference Citation Analysis]
9 Sedighi O, Makhlough A, Janbabai G, Neemi M. Comparative study of intravenous iron versus intravenous ascorbic Acid for treatment of functional iron deficiency in patients under hemodialysis: a randomized clinical trial. Nephrourol Mon 2013;5:913-7. [PMID: 24350091 DOI: 10.5812/numonthly.12038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
10 Kumar A, Sharma E, Marley A, Samaan MA, Brookes MJ. Iron deficiency anaemia: pathophysiology, assessment, practical management. BMJ Open Gastroenterol 2022;9:e000759. [PMID: 34996762 DOI: 10.1136/bmjgast-2021-000759] [Reference Citation Analysis]
11 Oh J, Joo KW, Chin HJ, Chae DW, Kim SG, Kim SJ, Chung W, Kim S, Huh W, Oh HY, Choi BS, Yang CW, Kim S. Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long-term hemodialysis. J Korean Med Sci 2014;29:76-83. [PMID: 24431909 DOI: 10.3346/jkms.2014.29.1.76] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
12 Suttorp MM, Hoekstra T, Rotmans JI, Ott I, Mittelman M, Krediet RT, Dekker FW. Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients. BMC Nephrol 2013;14:200. [PMID: 24066978 DOI: 10.1186/1471-2369-14-200] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
13 Morosetti M, Gorini A, Costanzo AM, Cipriani S, Dominijanni S, Egan CG, Zappalà L, di Luzio Paparatti U. Clinical management of nondialysis patients with chronic kidney disease: a retrospective observational study. Data from the SONDA study (Survey Of Non-Dialysis outpAtients). Int J Nephrol Renovasc Dis 2013;6:27-37. [PMID: 23550080 DOI: 10.2147/IJNRD.S38405] [Reference Citation Analysis]
14 Locatelli F, Mazzaferro S, Yee J. Iron Therapy Challenges for the Treatment of Nondialysis CKD Patients. Clin J Am Soc Nephrol 2016;11:1269-80. [PMID: 27185524 DOI: 10.2215/CJN.00080116] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
15 Miskulin DC, Weiner DE, Tighiouart H, Ladik V, Servilla K, Zager PG, Martin A, Johnson HK, Meyer KB; Medical Directors of Dialysis Clinic Inc. Computerized decision support for EPO dosing in hemodialysis patients. Am J Kidney Dis 2009;54:1081-8. [PMID: 19781831 DOI: 10.1053/j.ajkd.2009.07.010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
16 Li Y, Shi H, Wang WM, Peng A, Jiang GR, Zhang JY, Ni ZH, He LQ, Niu JY, Wang NS, Mei CL, Xu XD, Guo ZY, Yuan WJ, Yan HD, Deng YY, Yu C, Cen J, Zhang Y, Chen N. Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: First multicenter, cross-sectional study. Medicine (Baltimore) 2016;95:e3872. [PMID: 27310973 DOI: 10.1097/MD.0000000000003872] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
17 Seliger SL, Zhang AD, Weir MR, Walker L, Hsu VD, Parsa A, Diamantidis CJ, Fink JC. Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. Kidney Int 2011;80:288-94. [PMID: 21389972 DOI: 10.1038/ki.2011.49] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
18 Arneson TJ, Zaun D, Peng Y, Solid CA, Dunning S, Gilbertson DT. Comparison of methodologies to characterize haemoglobin variability in the US Medicare haemodialysis population. Nephrol Dial Transplant 2009;24:1378-83. [PMID: 19196826 DOI: 10.1093/ndt/gfp018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
19 McCormack PL. Ferumoxytol: in iron deficiency anaemia in adults with chronic kidney disease. Drugs 2012;72:2013-22. [PMID: 22994536 DOI: 10.2165/11209880-000000000-00000] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
20 Ahmed AM, Allam MF, Habil ES, Metwally AM, Ibrahiem NA, Radwan M, El-Gaafary MM, Afifi A, Gadallah MA. Development of practice guidelines for hemodialysis in Egypt. Indian J Nephrol 2010;20:193-202. [PMID: 21206681 DOI: 10.4103/0971-4065.73450] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
21 Kaysi S, Hadj Abdelkader M, Aniort J, Garrouste C, Philipponnet C, Deteix P, Heng AE. Chronic renal failure complications and management in kidney transplanted and nontransplanted patients. Transplant Proc 2012;44:2997-3000. [PMID: 23195013 DOI: 10.1016/j.transproceed.2012.05.084] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Hamano T, Fujii N, Hayashi T, Yamamoto H, Iseki K, Tsubakihara Y. Thresholds of iron markers for iron deficiency erythropoiesis-finding of the Japanese nationwide dialysis registry. Kidney Int Suppl (2011) 2015;5:23-32. [PMID: 26097782 DOI: 10.1038/kisup.2015.6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
23 Rink N, Zappitelli M. Estimation of glomerular filtration rate with and without height: effect of age and renal function level. Pediatr Nephrol 2015;30:1327-36. [PMID: 25854613 DOI: 10.1007/s00467-015-3063-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
24 Palamaner Subash Shantha G, Kumar AA, Sethi M, Khanna RC, Pancholy SB. Efficacy and safety of low molecular weight heparin compared to unfractionated heparin for chronic outpatient hemodialysis in end stage renal disease: systematic review and meta-analysis. PeerJ 2015;3:e835. [PMID: 25780780 DOI: 10.7717/peerj.835] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
25 Alcaide-Aldeano A, Garay A, Alcoberro L, Jiménez-Marrero S, Yun S, Tajes M, García-Romero E, Díez-López C, González-Costello J, Mateus-Porta G, Cainzos-Achirica M, Enjuanes C, Comín-Colet J, Moliner P. Iron Deficiency: Impact on Functional Capacity and Quality of Life in Heart Failure with Preserved Ejection Fraction. J Clin Med 2020;9:E1199. [PMID: 32331365 DOI: 10.3390/jcm9041199] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
26 Barandiarán Aizpurua A, Sanders-van Wijk S, Brunner-La Rocca HP, Henkens MTHM, Weerts J, Spanjers MHA, Knackstedt C, van Empel VPM. Iron deficiency impacts prognosis but less exercise capacity in heart failure with preserved ejection fraction. ESC Heart Fail 2021;8:1304-13. [PMID: 33522131 DOI: 10.1002/ehf2.13204] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Farrington CA, Robbin ML, Lee T, Barker-Finkel J, Allon M. Early Predictors of Arteriovenous Fistula Maturation: A Novel Perspective on an Enduring Problem. J Am Soc Nephrol 2020;31:1617-27. [PMID: 32424000 DOI: 10.1681/ASN.2019080848] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
28 Minutolo R, Chiodini P, Cianciaruso B, Pota A, Bellizzi V, Avino D, Mascia S, Laurino S, Bertino V, Conte G, De Nicola L. Epoetin therapy and hemoglobin level variability in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol 2009;4:552-9. [PMID: 19261821 DOI: 10.2215/CJN.04380808] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Alves MT, Vilaça SS, Carvalho Md, Fernandes AP, Dusse LM, Gomes KB. Resistance of dialyzed patients to erythropoietin. Rev Bras Hematol Hemoter 2015;37:190-7. [PMID: 26041422 DOI: 10.1016/j.bjhh.2015.02.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 3.1] [Reference Citation Analysis]
30 Chen TK, Estrella MM, Astor BC, Greene T, Wang X, Grams ME, Appel LJ. Longitudinal changes in hematocrit in hypertensive chronic kidney disease: results from the African-American Study of Kidney Disease and Hypertension (AASK). Nephrol Dial Transplant 2015;30:1329-35. [PMID: 25817226 DOI: 10.1093/ndt/gfv037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
31 Mikhail A. Profile of peginesatide and its potential for the treatment of anemia in adults with chronic kidney disease who are on dialysis. J Blood Med 2012;3:25-31. [PMID: 22719216 DOI: 10.2147/JBM.S23270] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
32 Van Wyck D, Eckardt K, Uhlig K, Rocco M, Levin A. Response to “Influence of Industry on Renal Guideline Development”: Figure 1. CJASN 2006;2:13-4. [DOI: 10.2215/cjn.03130906] [Cited by in Crossref: 9] [Article Influence: 0.6] [Reference Citation Analysis]
33 Quinlan C, Bates M, Sheils A, Dolan N, Riordan M, Awan A. Chronic hemodialysis in children weighing less than 10 kg. Pediatr Nephrol 2013;28:803-9. [DOI: 10.1007/s00467-012-2373-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
34 Kang SH, Kim AY, Do JY. Gastric antral vascular ectasia in a patient with lupus undergoing hemodialysis: a case report. BMC Nephrol 2020;21:468. [PMID: 33167896 DOI: 10.1186/s12882-020-02140-w] [Reference Citation Analysis]
35 Schmidt RJ. Methoxy polyethylene glycol-epoetin beta: worth waiting for or a novelty worn off? Expert Opinion on Pharmacotherapy 2009;10:1509-14. [DOI: 10.1517/14656560902997982] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
36 Francis C, Courbon G, Gerber C, Neuburg S, Wang X, Dussold C, Capella M, Qi L, Isakova T, Mehta R, Martin A, Wolf M, David V. Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease. Kidney Int 2019;96:1346-58. [PMID: 31668632 DOI: 10.1016/j.kint.2019.07.026] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
37 Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One. 2014;9:e84943. [PMID: 24392162 DOI: 10.1371/journal.pone.0084943] [Cited by in Crossref: 201] [Cited by in F6Publishing: 163] [Article Influence: 25.1] [Reference Citation Analysis]
38 George C, Matsha TE, Erasmus RT, Kengne AP. Haematological profile of chronic kidney disease in a mixed-ancestry South African population: a cross-sectional study. BMJ Open 2018;8:e025694. [PMID: 30391922 DOI: 10.1136/bmjopen-2018-025694] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
39 Ennis J, Gillen D, Rubenstein A, Worcester E, Brecher ME, Asplin J, Coe F. Clinical decision support improves physician guideline adherence for laboratory monitoring of chronic kidney disease: a matched cohort study. BMC Nephrol 2015;16:163. [PMID: 26471846 DOI: 10.1186/s12882-015-0159-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
40 Touzot M, Lefebvre T, Roux A, Maheas C, Ridel C, Puy H, Karim Z. Functional erythropoietin-hepcidin axis in recombinant human erythropoietin independent haemodialysis patients. Nephrology (Carlton) 2019;24:751-7. [PMID: 30175513 DOI: 10.1111/nep.13485] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Hansen RA, Chin H, Blalock S, Joy MS. Predialysis chronic kidney disease: evaluation of quality of life in clinic patients receiving comprehensive anemia care. Res Social Adm Pharm 2009;5:143-53. [PMID: 19524862 DOI: 10.1016/j.sapharm.2008.06.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
42 Metra M, Nodari S, Bordonali T, Bugatti S, Fontanella B, Lombardi C, Saporetti A, Verzura G, Danesi R, Dei Cas L. Anemia and heart failure: a cause of progression or only a consequence? Heart Int 2007;3:1. [PMID: 21977269 DOI: 10.4081/hi.2007.1] [Reference Citation Analysis]
43 Tsujita M, Kosugi T, Goto N, Futamura K, Nishihira M, Okada M, Hiramitsu T, Narumi S, Uchida K, Takeda A, Morozumi K, Maruyama S, Watarai Y. The effect of maintaining high hemoglobin levels on long-term kidney function in kidney transplant recipients: a randomized controlled trial. Nephrol Dial Transplant 2019;34:1409-16. [PMID: 30561729 DOI: 10.1093/ndt/gfy365] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
44 El-Nakib GA, Mostafa TM, Abbas TM, El-Shishtawy MM, Mabrouk MM, Sobh MA. Role of alpha-lipoic acid in the management of anemia in patients with chronic renal failure undergoing hemodialysis. Int J Nephrol Renovasc Dis 2013;6:161-8. [PMID: 24023521 DOI: 10.2147/IJNRD.S49066] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
45 Gobin J, Cernii A, McLean R, Finkelstein FO, Simon DB. Conversion from epoetin alfa to darbepoetin alfa for management of anaemia in a community chronic kidney disease centre: a retrospective cohort study. Clin Drug Investig 2011;31:113-20. [PMID: 21067252 DOI: 10.1007/BF03256938] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
46 Vela D. Systemic and local hepcidin as emerging and important peptides in renal homeostasis and pathology. Biofactors 2019;45:118-34. [PMID: 30461080 DOI: 10.1002/biof.1468] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
47 Akizawa T, Macdougall IC, Berns JS, Bernhardt T, Staedtler G, Taguchi M, Iekushi K, Krueger T. Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies. Am J Nephrol 2019;49:271-80. [PMID: 30852574 DOI: 10.1159/000499111] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
48 Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR; DRIVE Study Group. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007;18:975-84. [PMID: 17267740 DOI: 10.1681/ASN.2006091034] [Cited by in Crossref: 286] [Cited by in F6Publishing: 98] [Article Influence: 19.1] [Reference Citation Analysis]
49 Penne EL, van der Weerd NC, Grooteman MP, Mazairac AH, van den Dorpel MA, Nubé MJ, Bots ML, Lévesque R, ter Wee PM, Blankestijn PJ; CONTRAST investigators. Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients. Clin J Am Soc Nephrol 2011;6:281-9. [PMID: 21030579 DOI: 10.2215/CJN.04480510] [Cited by in Crossref: 66] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
50 Fan Y, Jin X, Man C, Gong D. Association of serum gamma-glutamyltransferase with chronic kidney disease risk: a meta-analysis. Free Radical Research 2018;52:819-25. [DOI: 10.1080/10715762.2018.1492120] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
51 Morgan HE, Holt RC, Jones CA, Judd BA. Intravenous iron treatment in paediatric chronic kidney disease patients not on erythropoietin. Pediatr Nephrol 2007;22:1963-5. [PMID: 17704954 DOI: 10.1007/s00467-007-0499-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
52 Xu Y, Ding XQ, Zou JZ, Liu ZH, Jiang SH, Chen YM. Serum hepcidin in haemodialysis patients: associations with iron status and microinflammation. J Int Med Res 2011;39:1961-7. [PMID: 22118000 DOI: 10.1177/147323001103900542] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
53 Soffritti S, Russo G, Cantelli S, Gilli G, Catizone L. Maintaining over time clinical performance targets on anaemia correction in unselected population on chronic dialysis at 20 Italian centres. Data from a retrospective study for a clinical audit. BMC Nephrol 2009;10:33. [PMID: 19852833 DOI: 10.1186/1471-2369-10-33] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
54 Hain DJ, Marinaro M, Koeper DW, Rosenthal MA, Chillemi S, Huffman JM, Gerbeling T, Pritsiolas JM, Loram LC, Pergola PE. Ferric citrate controls serum phosphorus in dialysis patients: retrospective data
. Clin Nephrol 2017;88:12-8. [PMID: 28561732 DOI: 10.5414/CN109057] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Li PKT, Choy ASM, Bavanandan S, Chen W, Foo M, Kanjanabuch T, Kim YL, Nakayama M, Yu X. Anemia Management in Peritoneal Dialysis: Perspectives From the Asia Pacific Region. Kidney Med 2021;3:405-11. [PMID: 34136787 DOI: 10.1016/j.xkme.2021.01.011] [Reference Citation Analysis]
56 Goyal H, Mohanty S, Sharma M, Rani A. Study of anemia in nondialysis dependent chronic kidney disease with special reference to serum hepcidin. Indian J Nephrol 2017;27:44-50. [PMID: 28182038 DOI: 10.4103/0971-4065.179301] [Cited by in Crossref: 5] [Article Influence: 1.0] [Reference Citation Analysis]
57 Kim IY, Kim JH, Kim MJ, Lee DW, Hwang CG, Han M, Rhee H, Song SH, Seong EY, Lee SB. Low 1,25-dihydroxyvitamin D level is associated with erythropoietin deficiency and endogenous erythropoietin resistance in patients with chronic kidney disease. Int Urol Nephrol 2018;50:2255-60. [PMID: 30136086 DOI: 10.1007/s11255-018-1967-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Clark EG, Barsuk JH. Temporary hemodialysis catheters: recent advances. Kidney Int 2014;86:888-95. [PMID: 24805107 DOI: 10.1038/ki.2014.162] [Cited by in Crossref: 38] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
59 Coyne DW, Fleming R. Will Targeting Interleukin-6 in the Anemia of CKD Change Our Treatment Paradigm? J Am Soc Nephrol 2021;32:6-8. [PMID: 33272966 DOI: 10.1681/ASN.2020101476] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Hwang HS, Song YM, Kim EO, Koh ES, Yoon HE, Chung SJ, Lee SJ, Chang YK, Yang CW, Chang YS, Kim SY. Decisive indicator for gastrointestinal workup in anemic patients with nondialysis chronic kidney disease. Int J Med Sci 2012;9:634-41. [PMID: 23055815 DOI: 10.7150/ijms.4969] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
61 Robles NR. The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease. Clin Drug Investig 2016;36:421-31. [PMID: 26894799 DOI: 10.1007/s40261-016-0378-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
62 Pai AB, Conner T, Mcquade CR, Olp J, Hicks P. Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose. Biometals 2011;24:603-13. [DOI: 10.1007/s10534-011-9409-6] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
63 Karaboyas A, Morgenstern H, Fleischer NL, Vanholder RC, Dhalwani NN, Schaeffner E, Schaubel DE, Akizawa T, James G, Sinsakul MV, Pisoni RL, Robinson BM. Inflammation and Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients: A Self-matched Longitudinal Study of Anemia Management in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Med 2020;2:286-96. [PMID: 32734248 DOI: 10.1016/j.xkme.2020.01.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
64 Sibbel SP, Koro CE, Brunelli SM, Cobitz AR. Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients. BMC Nephrol 2015;16:144. [PMID: 26283069 DOI: 10.1186/s12882-015-0138-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.9] [Reference Citation Analysis]
65 Maruyama T, Higuchi T, Yamazaki T, Okawa E, Ando H, Oikawa O, Inoshita A, Okada K, Abe M. Levocarnitine Injections Decrease the Need for Erythropoiesis-Stimulating Agents in Hemodialysis Patients with Renal Anemia. Cardiorenal Med 2017;7:188-97. [PMID: 28736559 DOI: 10.1159/000462983] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
66 Prasad N, Yadav AK, Kundu M, Sethi J, Jaryal A, Sircar D, Modi GK, Kamboj K, Sahay M, Gopalakrishnan N, Kaur P, Vikrant S, Varughese S, Baid-Agrawal S, Singh S, Gang S, Parameswaran S, Kumar V, Ghosh A, Jha V. Prescription Practices in Patients With Mild to Moderate CKD in India. Kidney Int Rep 2021;6:2455-62. [PMID: 34514206 DOI: 10.1016/j.ekir.2021.06.011] [Reference Citation Analysis]
67 Renders L, Budde K, Rosenberger C, van Swelm R, Swinkels D, Dellanna F, Feuerer W, Wen M, Erley C, Bader B, Sommerer C, Schaier M, Meurer K, Matis L. First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis. PLoS One 2019;14:e0212023. [PMID: 30917125 DOI: 10.1371/journal.pone.0212023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
68 Cozzolino M, Ciceri P, Galassi A, Mangano M, Carugo S, Capelli I, Cianciolo G. The Key Role of Phosphate on Vascular Calcification. Toxins (Basel) 2019;11:E213. [PMID: 30970562 DOI: 10.3390/toxins11040213] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 11.7] [Reference Citation Analysis]
69 Rosati A, Tetta C, Merello JI, Palomares I, Perez-Garcia R, Maduell F, Canaud B, Aljama Garcia P. Cumulative iron dose and resistance to erythropoietin. J Nephrol 2015;28:603-13. [PMID: 25091785 DOI: 10.1007/s40620-014-0127-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
70 Walton SM, Schumock GT. Should off-label drugs be included as comparators in pharmacoeconomic studies? Pharmacoeconomics 2014;32:1035-7. [PMID: 25270597 DOI: 10.1007/s40273-014-0222-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
71 Agarwal R, Leehey DJ, Olsen SM, Dahl NV. Proteinuria induced by parenteral iron in chronic kidney disease--a comparative randomized controlled trial. Clin J Am Soc Nephrol 2011;6:114-21. [PMID: 20876669 DOI: 10.2215/CJN.06020710] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
72 Mangion K, McDowell K, Mark PB, Rutherford E. Characterizing Cardiac Involvement in Chronic Kidney Disease Using CMR-a Systematic Review. Curr Cardiovasc Imaging Rep 2018;11:2. [PMID: 29497467 DOI: 10.1007/s12410-018-9441-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
73 Choi YA, Yoo SH, Song YM, Kim SY, Nam Y, Choi S, Kong BH, Yoon HE, Hong YA, Chang YK, Yang CW, Kim SY, Hwang HS. Diagnostic utility of immunochemical fecal occult blood tests to detect lower gastrointestinal lesions in patients with chronic kidney disease. Int J Colorectal Dis 2015;30:919-25. [PMID: 25868513 DOI: 10.1007/s00384-015-2200-3] [Reference Citation Analysis]
74 Sinha R, Saad A, Marks SD. Prevalence and complications of chronic kidney disease in paediatric renal transplantation: a K/DOQI perspective. Nephrol Dial Transplant. 2010;25:1313-1320. [PMID: 19926719 DOI: 10.1093/ndt/gfp600] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
75 Broumand B. Diabetes: changing the fate of diabetics in the dialysis unit. Blood Purif 2007;25:39-47. [PMID: 17170536 DOI: 10.1159/000096396] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
76 Balbino KP, Juvanhol LL, Epifânio APS, Marota LD, Bressan J, Hermsdorff HHM. Dietary intake as a predictor for all-cause mortality in hemodialysis subjects (NUGE-HD study). PLoS One 2019;14:e0226568. [PMID: 31846484 DOI: 10.1371/journal.pone.0226568] [Reference Citation Analysis]
77 Ohashi N, Sakao Y, Yasuda H, Kato A, Fujigaki Y. Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease. Int J Nephrol Renovasc Dis 2012;5:53-60. [PMID: 22536082 DOI: 10.2147/IJNRD.S23447] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
78 Wilson AC, Mitsnefes MM. Cardiovascular disease in CKD in children: update on risk factors, risk assessment, and management. Am J Kidney Dis 2009;54:345-60. [PMID: 19619845 DOI: 10.1053/j.ajkd.2009.04.027] [Cited by in Crossref: 48] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
79 Joy MS, Candiani C, Vaillancourt BA, Chin H, Hogan SL, Falk RJ. Reengineering Clinical Operations in a Medical Practice to Optimize the Management of Anemia of Chronic Kidney Disease. Pharmacotherapy 2007;27:734-44. [DOI: 10.1592/phco.27.5.734] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
80 Palaka E, Grandy S, van Haalen H, McEwan P, Darlington O. The Impact of CKD Anaemia on Patients: Incidence, Risk Factors, and Clinical Outcomes-A Systematic Literature Review. Int J Nephrol 2020;2020:7692376. [PMID: 32665863 DOI: 10.1155/2020/7692376] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
81 Santos EJF, Hortegal EV, Serra HO, Lages JS, Salgado-Filho N, Dos Santos AM. Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study. Braz J Med Biol Res 2018;51:e7288. [PMID: 29742267 DOI: 10.1590/1414-431x20187288] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
82 Waziri B, Mabayoje M, Bello B. Comparison of intravenous low molecular weight iron dextran and intravenous iron sucrose for the correction of anaemia in pre-dialysis chronic kidney disease patients: a randomized single-centre study in Nigeria. Clin Kidney J 2016;9:817-22. [PMID: 27994861 DOI: 10.1093/ckj/sfw064] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
83 Van Aelst LNL, Mazure D, Cohen-solal A. Towards Holistic Heart Failure Management—How to Tackle the Iron Deficiency Epidemic? Curr Heart Fail Rep 2017;14:223-34. [DOI: 10.1007/s11897-017-0338-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
84 Tannor EK, Norman BR, Adusei KK, Sarfo FS, Davids MR, Bedu-Addo G. Quality of life among patients with moderate to advanced chronic kidney disease in Ghana - a single centre study. BMC Nephrol 2019;20:122. [PMID: 30961570 DOI: 10.1186/s12882-019-1316-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
85 Koch TA, Myers J, Goodnough LT. Intravenous Iron Therapy in Patients with Iron Deficiency Anemia: Dosing Considerations. Anemia. 2015;2015:763576. [PMID: 26257955 DOI: 10.1155/2015/763576] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 5.1] [Reference Citation Analysis]
86 Kassirer JP. Stacking the Deck. CJASN 2007;2:212-212. [DOI: 10.2215/cjn.0660207] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
87 Coyne DW, Roger SD, Shin SK, Kim SG, Cadena AA, Moustafa MA, Chan TM, Besarab A, Chou W, Bradley C, Eyassu M, Leong R, Lee TT, Saikali KG, Szczech L, Yu KP. Roxadustat for CKD-related Anemia in Non-dialysis Patients. Kidney Int Rep 2021;6:624-35. [PMID: 33732977 DOI: 10.1016/j.ekir.2020.11.034] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
88 Cada DJ, Levien TL, Baker DE. Ferric carboxymaltose. Hosp Pharm 2014;49:52-9. [PMID: 24421564 DOI: 10.1310/hpj4901-52] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
89 Sofue T, Nakagawa N, Kanda E, Nagasu H, Matsushita K, Nangaku M, Maruyama S, Wada T, Terada Y, Yamagata K, Narita I, Yanagita M, Sugiyama H, Shigematsu T, Ito T, Tamura K, Isaka Y, Okada H, Tsuruya K, Yokoyama H, Nakashima N, Kataoka H, Ohe K, Okada M, Kashihara N. Prevalence of anemia in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). PLoS One 2020;15:e0236132. [PMID: 32687544 DOI: 10.1371/journal.pone.0236132] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
90 Baracco R, Saadeh S, Valentini R, Kapur G, Jain A, Mattoo TK. Iron deficiency in children with early chronic kidney disease. Pediatr Nephrol 2011;26:2077-80. [PMID: 21710251 DOI: 10.1007/s00467-011-1946-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
91 Hörl WH. Iron therapy for renal anemia: how much needed, how much harmful? Pediatr Nephrol 2007;22:480-9. [PMID: 17206511 DOI: 10.1007/s00467-006-0405-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
92 El-Kannishy GM, Megahed AF, Tawfik MM, El-Said G, Zakaria RT, Mohamed NA, Taha EM, Ammar AA, Abd Eltawab AM, Sayed-Ahmed NA. Obesity may be erythropoietin dose-saving in hemodialysis patients. Kidney Res Clin Pract 2018;37:148-56. [PMID: 29971210 DOI: 10.23876/j.krcp.2018.37.2.148] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
93 Schmidt RJ, Dalton CL. Treating anemia of chronic kidney disease in the primary care setting: cardiovascular outcomes and management recommendations. Osteopath Med Prim Care 2007;1:14. [PMID: 17910755 DOI: 10.1186/1750-4732-1-14] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
94 Foley RN, Wang C, Ishani A, Ibrahim HN, Collins AJ. Creatinine-based glomerular filtration rates and microalbuminuria for detecting metabolic abnormalities in US adults: the National Health and Nutrition Examination Survey 2003-2004. Am J Nephrol 2008;28:431-7. [PMID: 18097135 DOI: 10.1159/000112808] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
95 Elliott S. Erythropoiesis-stimulating agents and other methods to enhance oxygen transport. Br J Pharmacol 2008;154:529-41. [PMID: 18362898 DOI: 10.1038/bjp.2008.89] [Cited by in Crossref: 71] [Cited by in F6Publishing: 51] [Article Influence: 5.1] [Reference Citation Analysis]
96 Awdishu L, Moore T, Morrison M, Turner C, Trzebinska D. A Primer on Quality Assurance and Performance Improvement for Interprofessional Chronic Kidney Disease Care: A Path to Joint Commission Certification. Pharmacy (Basel) 2019;7:E83. [PMID: 31277293 DOI: 10.3390/pharmacy7030083] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
97 Hirth A, Edwards NC, Greve G, Tangeraas T, Gerdts E, Lenes K, Norgård G. Left ventricular function in children and adults after renal transplantation in childhood. Pediatr Nephrol 2012;27:1565-74. [PMID: 22527532 DOI: 10.1007/s00467-012-2167-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
98 Fishbane S, Pollack S, Feldman HI, Joffe MM. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. Clin J Am Soc Nephrol 2009;4:57-61. [PMID: 18987297 DOI: 10.2215/CJN.01670408] [Cited by in Crossref: 104] [Cited by in F6Publishing: 49] [Article Influence: 7.4] [Reference Citation Analysis]
99 Kuo KL, Hung SC, Wei YH, Tarng DC. Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. J Am Soc Nephrol 2008;19:1817-26. [PMID: 18495964 DOI: 10.1681/ASN.2007101084] [Cited by in Crossref: 65] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
100 Atkinson MA, Furth SL. Anemia in children with chronic kidney disease. Nat Rev Nephrol 2011;7:635-41. [PMID: 21894183 DOI: 10.1038/nrneph.2011.115] [Cited by in Crossref: 46] [Cited by in F6Publishing: 31] [Article Influence: 4.2] [Reference Citation Analysis]
101 Buttarello M, Pajola R, Novello E, Rebeschini M, Cantaro S, Oliosi F, Naso A, Plebani M. Diagnosis of Iron Deficiency in Patients Undergoing Hemodialysis. Am J Clin Pathol 2010;133:949-54. [DOI: 10.1309/ajcpqax0jfhfs0oa] [Cited by in Crossref: 46] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
102 van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, Mazairac AH, Nubé MJ, Penne EL, Gaillard CA, Wetzels JF, Wiegerinck ET, Swinkels DW, Blankestijn PJ, Ter Wee PM; CONTRAST Investigators. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents. PLoS One 2012;7:e39783. [PMID: 22808058 DOI: 10.1371/journal.pone.0039783] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
103 Gobin J, Cernii A, McLean R, Finkelstein FO, Simon DB. Conversion from epoetin alfa to darbepoetin alfa for management of anaemia in a community chronic kidney disease centre: a retrospective cohort study. Clin Drug Investig 2011;31:113-20. [PMID: 21067252 DOI: 10.1007/BF03256938] [Reference Citation Analysis]
104 Wang K, Wu J, Xu J, Gu S, Li Q, Cao P, Li M, Zhang Y, Zeng F. Correction of Anemia in Chronic Kidney Disease With Angelica sinensis Polysaccharide via Restoring EPO Production and Improving Iron Availability. Front Pharmacol 2018;9:803. [PMID: 30108502 DOI: 10.3389/fphar.2018.00803] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
105 Bamgbola O. Resistance to erythropoietin-stimulating agents: etiology, evaluation, and therapeutic considerations. Pediatr Nephrol 2012;27:195-205. [PMID: 21424525 DOI: 10.1007/s00467-011-1839-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
106 Bolignano D, Coppolino G, Romeo A, De Paola L, Buemi A, Lacquaniti A, Nicocia G, Lombardi L, Buemi M. Neutrophil gelatinase-associated lipocalin (NGAL) reflects iron status in haemodialysis patients. Nephrol Dial Transplant 2009;24:3398-403. [PMID: 19549696 DOI: 10.1093/ndt/gfp310] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
107 Ueda N, Takasawa K. Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease. Nutrients 2018;10:E1173. [PMID: 30150549 DOI: 10.3390/nu10091173] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 10.5] [Reference Citation Analysis]
108 Koo HM, Kim CH, Doh FM, Lee MJ, Kim EJ, Han JH, Han JS, Oh HJ, Park JT, Han SH, Yoo TH, Kang SW. The relationship of initial transferrin saturation to cardiovascular parameters and outcomes in patients initiating dialysis. PLoS One 2014;9:e87231. [PMID: 24505281 DOI: 10.1371/journal.pone.0087231] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
109 Fei M, Wen XQ, Yu ZL, Kang T, Wu WH, Ou ST. Roxadustat as treatment for a blood transfusion-dependent maintenance hemodialysis patient: A case report and review of literature. World J Clin Cases 2021; 9(15): 3680-3688 [PMID: 34046470 DOI: 10.12998/wjcc.v9.i15.3680] [Reference Citation Analysis]
110 Tentori F, Zhang J, Li Y, Karaboyas A, Kerr P, Saran R, Bommer J, Port F, Akiba T, Pisoni R, Robinson B. Longer dialysis session length is associated with better intermediate outcomes and survival among patients on in-center three times per week hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2012;27:4180-8. [PMID: 22431708 DOI: 10.1093/ndt/gfs021] [Cited by in Crossref: 114] [Cited by in F6Publishing: 92] [Article Influence: 11.4] [Reference Citation Analysis]
111 Becherucci F, Roperto RM, Materassi M, Romagnani P. Chronic kidney disease in children. Clin Kidney J 2016;9:583-91. [PMID: 27478602 DOI: 10.1093/ckj/sfw047] [Cited by in Crossref: 70] [Cited by in F6Publishing: 51] [Article Influence: 11.7] [Reference Citation Analysis]
112 Means RT. Anemia of Renal Failure/Chronic Kidney Disease. In: Means RT, editor. Anemia in the Young and Old. Cham: Springer International Publishing; 2019. pp. 147-56. [DOI: 10.1007/978-3-319-96487-4_8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
113 Szarnecka-Sojda A, Jacheć W, Polewczyk M, Łętek A, Miszczuk J, Polewczyk A. Risk of Complications and Survival of Patients Dialyzed with Permanent Catheters. Medicina (Kaunas) 2019;56:E2. [PMID: 31861701 DOI: 10.3390/medicina56010002] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
114 Munikrishnappa D. Chronic kidney disease (CKD) in the elderly -- a geriatrician's perspective. Aging Male 2007;10:113-37. [PMID: 17701657 DOI: 10.1080/13685530701419096] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
115 Rottembourg J, Tilleul P, Deray G, Lafuma A, Zakin L, Mahi L, Wernli J. Cost of managing anemia in end-stage renal disease: the experience of five French dialysis centers. Eur J Health Econ 2015;16:357-64. [PMID: 24570298 DOI: 10.1007/s10198-014-0571-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
116 Hayes W. Measurement of iron status in chronic kidney disease. Pediatr Nephrol 2019;34:605-13. [PMID: 29666917 DOI: 10.1007/s00467-018-3955-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
117 Lenz O, Fornoni A. Chronic kidney disease care delivered by US family medicine and internal medicine trainees: results from an online survey. BMC Med 2006;4:30. [PMID: 17164005 DOI: 10.1186/1741-7015-4-30] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
118 Hayat A. Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. Clin Med Res 2008;6:93-102. [PMID: 19325171 DOI: 10.3121/cmr.2008.811] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
119 Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23:1631-1634. [PMID: 22935483 DOI: 10.1681/asn.2011111078] [Cited by in Crossref: 352] [Cited by in F6Publishing: 194] [Article Influence: 35.2] [Reference Citation Analysis]
120 Frazão CM, de Sá JD, Medeiros AB, Fernandes MI, Lira AL, Lopes MV. The adaptation problems of patients undergoing hemodialysis: socio-economic and clinical aspects. Rev Lat Am Enfermagem 2014;22:966-72. [PMID: 25591091 DOI: 10.1590/0104-1169.3525.2504] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
121 Rivella S. Disorders of Red Cell Production and the Iron-Loading Anemias. In: Anderson GJ, Mclaren GD, editors. Iron Physiology and Pathophysiology in Humans. Totowa: Humana Press; 2012. pp. 321-41. [DOI: 10.1007/978-1-60327-485-2_16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
122 Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, Bradbury BD. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3:1077-1083. [PMID: 18417744 DOI: 10.2215/cjn.04601007] [Cited by in Crossref: 137] [Cited by in F6Publishing: 44] [Article Influence: 9.8] [Reference Citation Analysis]
123 Na HY, Lee YK, Shin SK, Yang DH, Cheon W, Park JH, Lee JH, Song JO, Jo YI. A randomized crossover study of single biweekly administration of epoetin-α compared with darbepoetin-α in chronic kidney disease patients not receiving dialysis. Kidney Res Clin Pract 2014;33:210-6. [PMID: 26885479 DOI: 10.1016/j.krcp.2014.10.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
124 Pagels AA, Söderkvist BK, Medin C, Hylander B, Heiwe S. Health-related quality of life in different stages of chronic kidney disease and at initiation of dialysis treatment. Health Qual Life Outcomes. 2012;10:71. [PMID: 22710013 DOI: 10.1186/1477-7525-10-71] [Cited by in Crossref: 103] [Cited by in F6Publishing: 88] [Article Influence: 10.3] [Reference Citation Analysis]
125 Ito H, Antoku S, Furusho M, Shinozaki M, Abe M, Mifune M, Togane M, Ito K, Sanaka T. The Prevalence of the Risk Factors for Atherosclerosis among Type 2 Diabetic Patients Is Greater in the Progressive Stages of Chronic Kidney Disease. Nephron Extra 2013;3:66-72. [PMID: 23904855 DOI: 10.1159/000353592] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
126 Atkinson MA, Martz K, Warady BA, Neu AM. Risk for anemia in pediatric chronic kidney disease patients: a report of NAPRTCS. Pediatr Nephrol 2010;25:1699-706. [PMID: 20464428 DOI: 10.1007/s00467-010-1538-6] [Cited by in Crossref: 41] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
127 Nagy A, Pethő D, Gáll T, Zavaczki E, Nyitrai M, Posta J, Zarjou A, Agarwal A, Balla G, Balla J. Zinc Inhibits HIF-Prolyl Hydroxylase Inhibitor-Aggravated VSMC Calcification Induced by High Phosphate. Front Physiol 2019;10:1584. [PMID: 32009983 DOI: 10.3389/fphys.2019.01584] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
128 Grabe DW. Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease. Am J Health Syst Pharm 2007;64:S8-14; quiz S23-5. [PMID: 17591995 DOI: 10.2146/ajhp070182] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
129 Qunibi WY. Is It Too Much of a Good Thing? A New Era in Phosphate Binder Therapy in ESRD. J Am Soc Nephrol 2015;26:2311-3. [PMID: 25736046 DOI: 10.1681/ASN.2015020135] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
130 Ponikowski P, Filippatos G, Colet JC, Willenheimer R, Dickstein K, Lüscher T, Gaudesius G, von Eisenhart Rothe B, Mori C, Greenlaw N, Ford I, Macdougall I, Anker SD; FAIR-HF Trial Investigators. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. Eur J Heart Fail 2015;17:329-39. [PMID: 25683972 DOI: 10.1002/ejhf.229] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 8.3] [Reference Citation Analysis]
131 Gardiner R, Roshan D, Brennan A, Connolly D, Murray S, Reddan D. Trends in the treatment of chronic kidney disease-associated anaemia in a cohort of haemodialysis patients: the Irish experience. Ir J Med Sci 2019;188:223-30. [PMID: 29704093 DOI: 10.1007/s11845-018-1823-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
132 Budde K, Rath T, Kliem V. Anemia control in kidney transplant recipients using once-monthly continuous erythropoietin receptor activator: a prospective, observational study. J Transplant 2014;2014:179705. [PMID: 24883202 DOI: 10.1155/2014/179705] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
133 Curran MP, McCormack PL. Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease. Drugs 2008;68:1139-56. [PMID: 18484803 DOI: 10.2165/00003495-200868080-00009] [Cited by in Crossref: 56] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
134 Whitman CB, Shreay S, Gitlin M, van Oijen MG, Spiegel BM. Clinical factors and the decision to transfuse chronic dialysis patients. Clin J Am Soc Nephrol 2013;8:1942-51. [PMID: 23929931 DOI: 10.2215/CJN.00160113] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
135 Monostori P, Kocsis GF, Ökrös Z, Bencsik P, Czétényi O, Kiss Z, Gellén B, Bereczki C, Ocsovszki I, Pipis J, Pálóczi J, Sárközy M, Török S, Varga IS, Kiss I, Fodor E, Csont T, Ferdinandy P, Túri S. Different administration schedules of darbepoetin alfa affect oxidized and reduced glutathione levels to a similar extent in 5/6 nephrectomized rats. Clin Exp Nephrol 2013;17:569-74. [PMID: 23224027 DOI: 10.1007/s10157-012-0749-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
136 Ito H, Takeuchi Y, Ishida H, Otawa A, Shibayama A, Antoku S, Abe M, Mifune M, Togane M. Mild anemia is frequent and associated with micro- and macroangiopathies in patients with type 2 diabetes mellitus. J Diabetes Investig 2010;1:273-8. [PMID: 24843443 DOI: 10.1111/j.2040-1124.2010.00060.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
137 Spinowitz B, Coyne DW, Lok CE, Fraticelli M, Azer M, Dalal S, Villa G, Rosansky S, Adamis H, Beyer U. C.E.R.A. Maintains Stable Control of Hemoglobin in Patients with Chronic Kidney Disease on Dialysis when Administered Once Every Two Weeks. Am J Nephrol 2008;28:280-9. [DOI: 10.1159/000111115] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
138 Rianthavorn P, Boonyapapong P. Ergocalciferol decreases erythropoietin resistance in children with chronic kidney disease stage 5. Pediatr Nephrol 2013;28:1261-6. [PMID: 23420502 DOI: 10.1007/s00467-013-2431-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
139 Gilbertson DT, Hu Y, Peng Y, Maroni BJ, Wetmore JB. Variability in hemoglobin levels in hemodialysis patients in the current era: a retrospective cohort study. Clin Nephrol 2017;88:254-65. [PMID: 28899480 DOI: 10.5414/CN109031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
140 Ijoma C, Ulasi I, Ijoma U, Ifebunandu N. High Prevalence of Anemia in Predialysis Patients in Enugu, Nigeria. Nephrology Research & Reviews 2010;2:61-5. [DOI: 10.4081/nr.2010.e14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
141 Panichi V, Scatena A, Rosati A, Giusti R, Ferro G, Malagnino E, Capitanini A, Piluso A, Conti P, Bernabini G, Migliori M, Caiani D, Tetta C, Casani A, Betti G, Pizzarelli F. High-volume online haemodiafiltration improves erythropoiesis-stimulating agent (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study. Nephrology Dialysis Transplantation 2015;30:682-9. [DOI: 10.1093/ndt/gfu345] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
142 Sinha SD, Bandi VK, Bheemareddy BR, Thakur P, Chary S, Mehta K, Pinnamareddy VR, Pandey R, Sreepada S, Durugkar S. Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial. BMC Nephrol 2019;20:90. [PMID: 30866856 DOI: 10.1186/s12882-019-1209-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
143 Macdougall IC, Strauss WE, McLaughlin J, Li Z, Dellanna F, Hertel J. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol 2014;9:705-12. [PMID: 24458078 DOI: 10.2215/CJN.05320513] [Cited by in Crossref: 58] [Cited by in F6Publishing: 31] [Article Influence: 7.3] [Reference Citation Analysis]
144 Xu Y, Alfaro-Magallanes VM, Babitt JL. Physiological and pathophysiological mechanisms of hepcidin regulation: clinical implications for iron disorders. Br J Haematol 2021;193:882-93. [PMID: 33316086 DOI: 10.1111/bjh.17252] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
145 Krischock LA, van Stralen KJ, Verrina E, Tizard EJ, Bonthuis M, Reusz G, Hussain FK, Jankauskiene A, Novljan G, Spasojević-dimitrijeva B, Podracka L, Zaller V, Jager KJ, Schaefer F; on behalf of the ESPN/ERA-EDTA Registry. Anemia in children following renal transplantation—results from the ESPN/ERA-EDTA Registry. Pediatr Nephrol 2016;31:325-33. [DOI: 10.1007/s00467-015-3201-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
146 Conway BN, Miller RG, Orchard TJ. Are hemoglobin levels elevated in type 1 diabetes? Diabetes Care 2010;33:341-3. [PMID: 19918013 DOI: 10.2337/dc09-0713] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
147 Kaze FF, Kengne AP, Mambap AT, Halle MP, Mbanya D, Ashuntantang G. Anemia in patients on chronic hemodialysis in Cameroon: prevalence, characteristics and management in low resources setting. Afr Health Sci 2015;15:253-60. [PMID: 25834556 DOI: 10.4314/ahs.v15i1.33] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
148 Maruyama T, Takashima H, Oguma H, Nakamura Y, Ohno M, Utsunomiya K, Furukawa T, Tei R, Abe M. Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease. Diabetes Technol Ther 2019;21:713-20. [PMID: 31385724 DOI: 10.1089/dia.2019.0212] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
149 Sule SD, Fadrowski JJ, Fivush BA, Gorman G, Furth SL. Reduced albumin levels and utilization of arteriovenous access in pediatric patients with systemic lupus erythematosus (SLE). Pediatr Nephrol 2007;22:2041-6. [DOI: 10.1007/s00467-007-0591-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
150 . Chapter 2: Use of iron to treat anemia in CKD. Kidney Int Suppl (2011) 2012;2:292-8. [PMID: 25018949 DOI: 10.1038/kisup.2012.34] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
151 Charytan C, Manllo-Karim R, Martin ER, Steer D, Bernardo M, Dua SL, Moustafa MA, Saha G, Bradley C, Eyassu M, Leong R, Saikali KG, Liu C, Szczech L, Yu KP. A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study. Kidney Int Rep 2021;6:1829-39. [PMID: 34307977 DOI: 10.1016/j.ekir.2021.04.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
152 Atkinson MA, White CT. Hepcidin in anemia of chronic kidney disease: review for the pediatric nephrologist. Pediatr Nephrol 2012;27:33-40. [PMID: 21400189 DOI: 10.1007/s00467-011-1832-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
153 de Francisco AL. Individualizing anaemia therapy. NDT Plus 2010;3:519-26. [PMID: 25949459 DOI: 10.1093/ndtplus/sfq164] [Reference Citation Analysis]
154 Üstündağ S, Doğan E, Duranay M, Kazancıoğlu R, Çelik V, Ünsal A, Altıntepe L, Dursun B, Akbaş E, Özdener F, Yıldız A. Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anemia in Predialysis Patients. Balkan Med J 2016;33:322-30. [PMID: 27308077 DOI: 10.5152/balkanmedj.2016.141173] [Reference Citation Analysis]
155 Ingrasciotta Y, Lacava V, Marcianò I, Giorgianni F, Tripepi G, D' Arrigo G, Chinellato A, Ugo Tari D, Santoro D, Trifirò G. In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study. BMC Nephrol 2019;20:359. [PMID: 31521117 DOI: 10.1186/s12882-019-1554-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
156 Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. Prim Care. 2008;35:329-344, vii. [PMID: 18486718 DOI: 10.1016/j.pop.2008.01.008] [Cited by in Crossref: 177] [Cited by in F6Publishing: 133] [Article Influence: 12.6] [Reference Citation Analysis]
157 Ryu WS, Kim CK, Kim BJ, Lee SH. Serum uric acid levels and cerebral microbleeds in patients with acute ischemic stroke. PLoS One 2013;8:e55210. [PMID: 23372838 DOI: 10.1371/journal.pone.0055210] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
158 Williams AW, Dwyer AC, Eddy AA, Fink JC, Jaber BL, Linas SL, Michael B, O'Hare AM, Schaefer HM, Shaffer RN, Trachtman H, Weiner DE, Falk AR; American Society of Nephrology Quality, and Patient Safety Task Force. Critical and honest conversations: the evidence behind the "Choosing Wisely" campaign recommendations by the American Society of Nephrology. Clin J Am Soc Nephrol 2012;7:1664-72. [PMID: 22977214 DOI: 10.2215/CJN.04970512] [Cited by in Crossref: 125] [Cited by in F6Publishing: 63] [Article Influence: 12.5] [Reference Citation Analysis]
159 Fuller DS, Robinson BM. Facility Practice Variation to Help Understand the Effects of Public Policy: Insights from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol 2017;12:190-9. [PMID: 28062678 DOI: 10.2215/CJN.03930416] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
160 Che J, Yang J, Zhao B, Zhang G, Wang L, Peng S, Shang P. The Effect of Abnormal Iron Metabolism on Osteoporosis. Biol Trace Elem Res 2020;195:353-65. [PMID: 31473898 DOI: 10.1007/s12011-019-01867-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
161 Sule SD, Fadrowski JJ, Fivush BA, Neu AM, Furth SL. Persistent low albumin and temporary vascular access in pediatric patients with SLE on hemodialysis. Pediatr Nephrol 2009;24:1981-7. [PMID: 19526255 DOI: 10.1007/s00467-009-1227-5] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
162 . Chapter 3: Use of ESAs and other agents to treat anemia in CKD. Kidney Int Suppl (2011) 2012;2:299-310. [PMID: 25018950 DOI: 10.1038/kisup.2012.35] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
163 Coyne DW. Influence of Industry on Renal Guideline Development: Figure 1. CJASN 2006;2:3-7. [DOI: 10.2215/cjn.02170606] [Cited by in Crossref: 56] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
164 Tantisattamo E, Murray V, Obi Y, Park C, Catabay CJ, Lee Y, Wenziger C, Hsiung JT, Soohoo M, Kleine CE, Rhee CM, Kraut J, Kovesdy CP, Kalantar-Zadeh K, Streja E. Association of Pre-ESRD Serum Bicarbonate with Post-ESRD Mortality in Patients with Incident ESRD. Am J Nephrol 2021;52:304-17. [PMID: 33895727 DOI: 10.1159/000513855] [Reference Citation Analysis]
165 Urrechaga E, Borque L, Escanero JF. Potential utility of the new Sysmex XE 5000 red blood cell extended parameters in the study of disorders of iron metabolism. Clinical Chemistry and Laboratory Medicine 2009;47. [DOI: 10.1515/cclm.2009.301] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
166 Lea JP, Norris K, Agodoa L. The role of anemia management in improving outcomes for African-Americans with chronic kidney disease. Am J Nephrol 2008;28:732-43. [PMID: 18434712 DOI: 10.1159/000127981] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
167 van der Weerd NC, Den Hoedt CH, Blankestijn PJ, Bots ML, van den Dorpel MA, Lévesque R, Mazairac AH, Nubé MJ, Penne EL, ter Wee PM, Grooteman MP; CONTRAST Investigators. Resistance to erythropoiesis stimulating agents in patients treated with online hemodiafiltration and ultrapure low-flux hemodialysis: results from a randomized controlled trial (CONTRAST). PLoS One 2014;9:e94434. [PMID: 24743493 DOI: 10.1371/journal.pone.0094434] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
168 Hara T, Mukai H, Nakashima T, Sagara R, Furusho M, Miura S, Toyonaga J, Sugawara K, Takeda K. Factors Contributing to Erythropoietin Hyporesponsiveness in Patients on Long-Term Continuous Ambulatory Peritoneal Dialysis: A Cross-Sectional Study. Nephron Extra 2015;5:79-86. [PMID: 26648974 DOI: 10.1159/000441154] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
169 Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis. 2010;55:726-741. [PMID: 20189278 DOI: 10.1053/j.ajkd.2009.12.030] [Cited by in Crossref: 132] [Cited by in F6Publishing: 118] [Article Influence: 11.0] [Reference Citation Analysis]
170 Jing Z, Wei-jie Y, Nan Z, Yi Z, Ling W. Hemoglobin targets for chronic kidney disease patients with anemia: a systematic review and meta-analysis. PLoS One 2012;7:e43655. [PMID: 22952731 DOI: 10.1371/journal.pone.0043655] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
171 Bakkaloğlu SA, Kandur Y, Serdaroğlu E, Noyan A, Bayazıt AK, Taşdemir M, Özlü SG, Özçelik G, Dursun İ, Alparslan C, Akcaboy M, Atikel YÖ, Parmaksız G, Atmış B, Sever L. Time-averaged hemoglobin values, not hemoglobin cycling, have an impact on outcomes in pediatric dialysis patients. Pediatr Nephrol 2018;33:2143-50. [PMID: 30105415 DOI: 10.1007/s00467-018-4013-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
172 Ishani A, Guo H, Arneson TJ, Gilbertson DT, Mau LW, Li S, Dunning S, Collins AJ. Possible effects of the new Medicare reimbursement policy on African Americans with ESRD. J Am Soc Nephrol 2009;20:1607-13. [PMID: 19389846 DOI: 10.1681/ASN.2008080853] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
173 Aryee C, Owiredu WK, Osei-Yeboah J, Owusu-Dabo E, Laing EF, Owusu IK. An Analysis of Anthropometric Indicators and Modifiable Lifestyle Parameters Associated with Hypertensive Nephropathy. Int J Hypertens 2016;2016:6598921. [PMID: 27774313 DOI: 10.1155/2016/6598921] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
174 Watschinger B, Salmhofer H, Horn S, Neyer U, Wiesinger T, Wiesholzer M, Erb H, Jaeger C, Hemetsberger M, Rosenkranz AR. The MAINTAIN study--managing hemoglobin variability with darbepoetin alfa in dialysis patients experiencing a severe drop in hemoglobin. Wien Klin Wochenschr 2013;125:71-82. [PMID: 23299452 DOI: 10.1007/s00508-012-0311-1] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
175 Joshi AD, Holdford DA, Brophy DF, Harpe SE, Mays D, Gehr TW. Utilization Patterns of IV Iron and Erythropoiesis Stimulating Agents in Anemic Chronic Kidney Disease Patients: A Multihospital Study. Anemia 2012;2012:248430. [PMID: 22577528 DOI: 10.1155/2012/248430] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
176 Macdougall IC, Bock A, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Roubert B, Cushway T, Roger SD; FIND-CKD Study Investigators. The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale. Nephrol Dial Transplant 2014;29:843-50. [PMID: 24170814 DOI: 10.1093/ndt/gft424] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
177 Röhrig G, Doehner W, Schaefer R, Schulz R. Anämie und Eisenmangel in der Geriatrie: Prävalenz, Diagnostik und neue Therapieoptionen. Z Gerontol Geriat 2012;45:191-6. [DOI: 10.1007/s00391-012-0320-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
178 Fernando WBNT, Hettiarachchi TW, Sudeshika T, Badurdeen Z, Abeysundara H, Ranasinghe S, Rathnayake MP, Nanayakkara N. Snap shot view on anaemia in chronic kidney disease of uncertain aetiology. Nephrology 2019;24:1033-40. [DOI: 10.1111/nep.13545] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
179 Aurshina A, Hingorani A, Alsheekh A, Kibrik P, Marks N, Ascher E. Placement issues of hemodialysis catheters with pre-existing central lines and catheters. J Vasc Access 2018;19:366-9. [PMID: 29542366 DOI: 10.1177/1129729818757964] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
180 Mutell R, Rubin JL, Bond TC, Mayne T. Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model. Int J Nephrol Renovasc Dis. 2013;6:79-87. [PMID: 23662073 DOI: 10.2147/ijnrd.s40729] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 0.2] [Reference Citation Analysis]
181 Kerr PG. Renal anaemia: recent developments, innovative approaches and future directions for improved management. Nephrology (Carlton) 2006;11:542-8. [PMID: 17199795 DOI: 10.1111/j.1440-1797.2006.00701.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
182 Palazzuoli A, Ruocco G, Pellegrini M, De Gori C, Del Castillo G, Giordano N, Nuti R. The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions. Ther Clin Risk Manag. 2014;10:641-650. [PMID: 25143739 DOI: 10.2147/tcrm.s61551] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
183 Coyne DW. PIVOTAL trial: iron loading improves clinical outcomes. Nat Rev Nephrol 2019;15:260-1. [DOI: 10.1038/s41581-019-0128-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
184 Atkinson MA, Joo S, Sule S. Hepcidin and arterial stiffness in children with systemic lupus erythematosus and lupus nephritis: A cross-sectional study. PLoS One 2019;14:e0214248. [PMID: 30925172 DOI: 10.1371/journal.pone.0214248] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
185 Ferrari P, Kulkarni H, Dheda S, Betti S, Harrison C, St Pierre TG, Olynyk JK. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol 2011;6:77-83. [PMID: 20876673 DOI: 10.2215/CJN.04190510] [Cited by in Crossref: 89] [Cited by in F6Publishing: 32] [Article Influence: 7.4] [Reference Citation Analysis]
186 Pollak VE, Lorch JA, Shukla R, Satwah S. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data. BMC Nephrol 2009;10:6. [PMID: 19245700 DOI: 10.1186/1471-2369-10-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
187 Gilmartin C. Pharmacist's role in managing anemia in patients with chronic kidney disease: potential clinical and economic benefits. Am J Health Syst Pharm 2007;64:S15-22; quiz S23-5. [PMID: 17591991 DOI: 10.2146/ajhp070183] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
188 Spinowitz BS, Kausz AT, Baptista J, Noble SD, Sothinathan R, Bernardo MV, Brenner L, Pereira BJ. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008;19:1599-605. [PMID: 18525001 DOI: 10.1681/ASN.2007101156] [Cited by in Crossref: 175] [Cited by in F6Publishing: 82] [Article Influence: 12.5] [Reference Citation Analysis]
189 Murphy L, Gray A, Joyce E. Anabolism to Catabolism: Serologic Clues to Nutritional Status in Heart Failure. Curr Heart Fail Rep 2019;16:189-200. [PMID: 31606846 DOI: 10.1007/s11897-019-00437-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
190 Silva GP, Elena CDV, Carneiro FP, Veiga JPR. Effect of systemic inflammation on level of ferritin seminal in chronic renal male patient undergoing hemodialysis. Int Arch Med 2014;7:23. [PMID: 24834129 DOI: 10.1186/1755-7682-7-23] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
191 Feng L, Jin AZ, Allen JC, Chow KY, Jafar TH. Timing of commencement of maintenance dialysis and mortality in young and older adults in Singapore. BMC Nephrol 2017;18:176. [PMID: 28558717 DOI: 10.1186/s12882-017-0590-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
192 Heringlake M, Kindgen-milles D, Hackmann F, Haake N, Kielstein J, Lance M, Lufft H, Just S, Trabold B, Scherlitz A, Schirmer U, Schmitt D, Vargas-hein O, Markewitz A. Pathophysiologie, Prophylaxe und Therapie von Herzchirurgie-assoziierten Nierenfunktionsstörungen: Eine Stellungnahme der Arbeitsgruppe Niere des gemeinschaftlichen Arbeitskreises Intensivmedizin von DGAI und DGTHG unter Berücksichtigung der Konsensus-Empfehlungen der Acute Dialysis Quality Initiative. Z Herz- Thorax- Gefäßchir 2009;23:349-73. [DOI: 10.1007/s00398-009-0743-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
193 Tsuruya K, Torisu K, Yoshida H, Yamada S, Tanaka S, Tsuchimoto A, Eriguchi M, Fujisaki K, Masutani K, Kitazono T. Positive association of residual kidney function with hemoglobin level in patients on peritoneal dialysis independent of endogenous erythropoietin concentration. Ren Replace Ther 2017;3. [DOI: 10.1186/s41100-017-0126-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
194 Loutradis C, Skodra A, Georgianos P, Tolika P, Alexandrou D, Avdelidou A, Sarafidis PA. Diabetes mellitus increases the prevalence of anemia in patients with chronic kidney disease: A nested case-control study. World J Nephrol 2016; 5(4): 358-366 [PMID: 27458564 DOI: 10.5527/wjn.v5.i4.358] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
195 Brunelli SM, Sibbel SP, Van Wyck D, Sharma A, Hsieh A, Chertow GM. Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Model. Drugs R D 2017;17:159-66. [PMID: 28078600 DOI: 10.1007/s40268-016-0163-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
196 Cosgrove L, Shaughnessy AF, Shaneyfelt T. When is a guideline not a guideline? The devil is in the details. BMJ Evid Based Med 2018;23:33-6. [PMID: 29367325 DOI: 10.1136/ebmed-2017-110845] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
197 Rattanasompattikul M, Molnar MZ, Zaritsky JJ, Hatamizadeh P, Jing J, Norris KC, Kovesdy CP, Kalantar-Zadeh K. Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients. Nephrol Dial Transplant 2013;28:1936-45. [PMID: 23045431 DOI: 10.1093/ndt/gfs368] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 4.7] [Reference Citation Analysis]
198 Weng PL, Alejos JC, Halnon N, Zhang Q, Reed EF, Tsai Chambers E. Long-term outcomes of simultaneous heart and kidney transplantation in pediatric recipients. Pediatr Transplant 2017;21. [PMID: 28727227 DOI: 10.1111/petr.13023] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
199 Urrechaga E, Hoffmann JJML. Assessment of iron-restricted erythropoiesis in chronic renal disease: evaluation of Abbott CELL-DYN Sapphire mean reticulocyte hemoglobin content (MCHr). Scandinavian Journal of Clinical and Laboratory Investigation 2019;79:363-7. [DOI: 10.1080/00365513.2019.1622149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
200 Murphy WJA, Steiber A, Connery GC, Carder J, Spry L, Hoppel C. Altered carnitine metabolism in dialysis patients with reduced physical function may be due to dysfunctional fatty acid oxidation. Nephrology Dialysis Transplantation 2012;27:304-10. [DOI: 10.1093/ndt/gfr334] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
201 Cases A, Portolés J, Calls J, Martinez-Castelao A, Munar MA, Segarra A. Beneficial dose conversion after switching from higher doses of shorter-acting erythropoiesis-stimulating agents to C.E.R.A in CKD patients in clinical practice: MINERVA Study. Int Urol Nephrol 2014;46:1983-95. [PMID: 25118611 DOI: 10.1007/s11255-014-0800-4] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
202 Carrera F, Burnier M. Use of darbepoetin alfa in the treatment of anaemia of chronic kidney disease: clinical and pharmacoeconomic considerations. NDT Plus 2009;2:i9-i17. [PMID: 19461859 DOI: 10.1093/ndtplus/sfn175] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
203 Akizawa T, Iwasaki M, Otsuka T, Reusch M, Misumi T. Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial. Adv Ther 2019;36:1438-54. [PMID: 30953333 DOI: 10.1007/s12325-019-00943-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 9.7] [Reference Citation Analysis]
204 Halle MP, Zebaze PN, Mbofung CM, Kaze F, Mbiatat H, Ashuntantang G, Kengne AP. Nutritional status of patients on maintenance hemodialysis in urban sub-Saharan Africa: evidence from Cameroon. J Nephrol 2014;27:545-53. [PMID: 24477981 DOI: 10.1007/s40620-014-0047-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
205 Gonçalves SM, Dal Lago EA, de Moraes TP, Kloster SC, Boros G, Colombo M, Raboni L, Olandoski M, Fernandes N, Qureshi AR, Divino Filho JC, Pecoits-Filho R; BRAZPD Study Investigators. Lack of adequate predialyis care and previous hemodialysis, but not hemoglobin variability, are independent predictors of anemia-associated mortality in incident Brazilian peritoneal dialysis patients: results from the BRAZPD study. Blood Purif 2012;34:298-305. [PMID: 23235144 DOI: 10.1159/000342618] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
206 Sui Z, Wang M, Zuo L. Statin therapy and erythropoiesis-stimulating agent hyporesponsiveness in patients with nondialysis chronic kidney disease: A retrospective study in Beijing, China. Medicine (Baltimore) 2019;98:e13981. [PMID: 30633179 DOI: 10.1097/MD.0000000000013981] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
207 Wärme A, Hadimeri H, Nasic S, Stegmayr B. The association of erythropoietin-stimulating agents and increased risk for AV-fistula dysfunction in hemodialysis patients. A retrospective analysis. BMC Nephrol 2021;22:30. [PMID: 33461526 DOI: 10.1186/s12882-020-02209-6] [Reference Citation Analysis]
208 Browne SA, Reddan D. Potential role of bone morphogenetic protein (BMP) signalling as a potential therapeutic target for modification of iron balance. Nephrology Dialysis Transplantation 2008;24:28-30. [DOI: 10.1093/ndt/gfn551] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
209 Atkinson MA, Melamed ML, Kumar J, Roy CN, Miller ER 3rd, Furth SL, Fadrowski JJ. Vitamin D, race, and risk for anemia in children. J Pediatr 2014;164:153-158.e1. [PMID: 24112861 DOI: 10.1016/j.jpeds.2013.08.060] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 4.7] [Reference Citation Analysis]
210 González MT, Ramos R, Vera M, Barbosa F, Garcia C, Garcia I, González-Segura C, Cuxart M, Teixidó J, José de la Cruz J. Monthly CERA treatment maintains stable hemoglobin levels in routine clinical practice of peritoneal dialysis patients. Ren Fail 2013;35:314-9. [PMID: 23356501 DOI: 10.3109/0886022X.2012.755903] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
211 Aoun M, Karam R, Sleilaty G, Antoun L, Ammar W. Iron deficiency across chronic kidney disease stages: Is there a reverse gender pattern? PLoS One 2018;13:e0191541. [PMID: 29357391 DOI: 10.1371/journal.pone.0191541] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
212 Tomasz G, Ewa W, Jolanta M. Biomarkers of iron metabolism in chronic kidney disease. Int Urol Nephrol 2021;53:935-44. [PMID: 33025407 DOI: 10.1007/s11255-020-02663-z] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
213 Garattini S, Perico N. Drug development: how academia, industry and authorities interact. Nat Rev Nephrol 2014;10:602-10. [PMID: 25092151 DOI: 10.1038/nrneph.2014.133] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
214 Azocar M, Quiroz L, Delucchi A, Dinamarca H, Emilfork M, Cano F. The plasma permeability factor in nephrotic syndrome: indirect evidence in pediatric peritoneal dialysis. Perit Dial Int 2012;32:437-43. [PMID: 22473035 DOI: 10.3747/pdi.2009.00251] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
215 Tonks A. Too much of a good thing. BMJ 2007;334:978-80. [PMID: 17494015 DOI: 10.1136/bmj.39198.510347.AD] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
216 Lee Y, Nam HY, Kim J, Lee M, Yockman JW, Shin SK, Kim SW. Human erythropoietin gene delivery using an arginine-grafted bioreducible polymer system. Mol Ther 2012;20:1360-6. [PMID: 22472948 DOI: 10.1038/mt.2012.62] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
217 Viswanathan G, Sarnak MJ, Tighiouart H, Muntner P, Inker LA. The association of chronic kidney disease complications by albuminuria and glomerular filtration rate: a cross-sectional analysis. Clin Nephrol 2013;80:29-39. [PMID: 23803596 DOI: 10.5414/cn107842] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
218 Kumar U, Wettersten N, Garimella PS. Cardiorenal Syndrome: Pathophysiology. Cardiol Clin. 2019;37:251-265. [PMID: 31279419 DOI: 10.1016/j.ccl.2019.04.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
219 Butterfield JM, Mueller BA, Patel N, Cardone KE, Grabe DW, Salama NN, Lodise TP. Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis. Antimicrob Agents Chemother. 2013;57:864-872. [PMID: 23208714 DOI: 10.1128/aac.02000-12] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
220 Groenendaal-van de Meent D, Kerbusch V, Kaspera R, Barroso-Fernandez B, Galletti P, Klein GK, den Adel M. Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor. Eur J Drug Metab Pharmacokinet 2021;46:141-53. [PMID: 33165773 DOI: 10.1007/s13318-020-00658-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
221 Agarwal R, Davis JL, Smith L. Serum albumin is strongly associated with erythropoietin sensitivity in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:98-104. [PMID: 18045859 DOI: 10.2215/CJN.03330807] [Cited by in Crossref: 42] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
222 Atkinson MA, Pierce CB, Fadrowski JJ, Benador NM, White CT, Turman MA, Pan CG, Abraham AG, Warady BA, Furth SL. Association between common iron store markers and hemoglobin in children with chronic kidney disease. Pediatr Nephrol 2012;27:2275-83. [PMID: 22836305 DOI: 10.1007/s00467-012-2266-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
223 Inker LA, Tonelli M, Hemmelgarn BR, Levitan EB, Muntner P. Comparison of concurrent complications of CKD by 2 risk categorization systems. Am J Kidney Dis 2012;59:372-81. [PMID: 22113126 DOI: 10.1053/j.ajkd.2011.09.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
224 Grotto HZ. Platelet and reticulocyte new parameters: why and how to use them? Rev Bras Hematol Hemoter 2016;38:283-4. [PMID: 27863753 DOI: 10.1016/j.bjhh.2016.08.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
225 Novak JE, Szczech LA. Triumph and tragedy: anemia management in chronic kidney disease: . Current Opinion in Nephrology and Hypertension 2008;17:580-8. [DOI: 10.1097/mnh.0b013e32830c488d] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
226 Shavit L, Hitti S, Silberman S, Tauber R, Merin O, Lifschitz M, Slotki I, Bitran D, Fink D. Preoperative hemoglobin and outcomes in patients with CKD undergoing cardiac surgery. Clin J Am Soc Nephrol. 2014;9:1536-1544. [PMID: 24993450 DOI: 10.2215/cjn.00110114] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
227 Ogawa C, Tsuchiya K, Tomosugi N, Kanda F, Maeda K, Maeda T. Low levels of serum ferritin and moderate transferrin saturation lead to adequate hemoglobin levels in hemodialysis patients, retrospective observational study. PLoS One 2017;12:e0179608. [PMID: 28662118 DOI: 10.1371/journal.pone.0179608] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
228 Neven E, De Schutter TM, Behets GJ, Gupta A, D'Haese PC. Iron and vascular calcification. Is there a link? Nephrol Dial Transplant 2011;26:1137-45. [PMID: 21325349 DOI: 10.1093/ndt/gfq858] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
229 Conway B, Fried L, Orchard T. Hemoglobin and overt nephropathy complications in type 1 diabetes. Ann Epidemiol 2008;18:147-55. [PMID: 18083536 DOI: 10.1016/j.annepidem.2007.07.110] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
230 Park JI, Kim TY, Oh B, Cho H, Kim JE, Yoo SH, Lee JP, Kim YS, Chun J, Kim BS, Lee H. Comparative analysis of the tonsillar microbiota in IgA nephropathy and other glomerular diseases. Sci Rep 2020;10:16206. [PMID: 33004860 DOI: 10.1038/s41598-020-73035-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
231 Gallo CJR, Mammarappallil JG, Johnson DY, Chalian H, Ronald J, Bashir MR, Kim CY. Ferumoxytol-enhanced MR Venography of the Central Veins of the Thorax for the Evaluation of Stenosis and Occlusion in Patients with Renal Impairment. Radiol Cardiothorac Imaging 2020;2:e200339. [PMID: 33778639 DOI: 10.1148/ryct.2020200339] [Reference Citation Analysis]
232 Nasir N, Raji S, Mustafa F, Rizvi TA, Al Natour Z, Hilal-Alnaqbi A, Al Ahmad M. Electrical detection of blood cells in urine. Heliyon 2020;6:e03102. [PMID: 31909269 DOI: 10.1016/j.heliyon.2019.e03102] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
233 Dev S, Babitt JL. Overview of iron metabolism in health and disease. Hemodial Int 2017;21 Suppl 1:S6-S20. [PMID: 28296010 DOI: 10.1111/hdi.12542] [Cited by in Crossref: 103] [Cited by in F6Publishing: 95] [Article Influence: 20.6] [Reference Citation Analysis]
234 Thilly N, Stengel B, Boini S, Villar E, Couchoud C, Frimat L. Evaluation and determinants of underprescription of erythropoiesis stimulating agents in pre-dialysis patients with anaemia. Nephron Clin Pract 2008;108:c67-74. [PMID: 18182782 DOI: 10.1159/000112914] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
235 Urrechaga E, Borque L, Escanero JF. Erythrocyte and Reticulocyte Indices on the LH 750 as Potential Markers of Functional Iron Deficiency. Anemia 2010;2010:625919. [PMID: 21490909 DOI: 10.1155/2010/625919] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
236 Alfrey CP, Fishbane S. Implications of Neocytolysis for Optimal Management of Anaemia in Chronic Kidney Disease. Nephron Clin Pract 2007;106:c149-56. [DOI: 10.1159/000104425] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
237 Sultana T, DeVita MV, Michelis MF. Oral vitamin C supplementation reduces erythropoietin requirement in hemodialysis patients with functional iron deficiency. Int Urol Nephrol 2016;48:1519-24. [PMID: 27170339 DOI: 10.1007/s11255-016-1309-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
238 Pan SY, Chiang WC, Chen PM, Liu HH, Chou YH, Lai TS, Lai CF, Chiu YL, Lin WY, Chen YM, Chu TS, Lin SL. Restricted Use of Erythropoiesis-Stimulating Agent is Safe and Associated with Deferred Dialysis Initiation in Stage 5 Chronic Kidney Disease. Sci Rep 2017;7:44013. [PMID: 28272424 DOI: 10.1038/srep44013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
239 Rubin RJ, Mendelson DN. Translating Guidelines into Policy. CJASN 2007;2:209-10. [DOI: 10.2215/cjn.00260107] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
240 Fadrowski JJ, Pierce CB, Cole SR, Moxey-Mims M, Warady BA, Furth SL. Hemoglobin decline in children with chronic kidney disease: baseline results from the chronic kidney disease in children prospective cohort study. Clin J Am Soc Nephrol 2008;3:457-62. [PMID: 18235140 DOI: 10.2215/CJN.03020707] [Cited by in Crossref: 48] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
241 Mullins CD, Jain R, Weir MR, Franey CS, Shih YC, Pradel FG, Bikov K, Bartlett ST. Benefits Improvement and Protection Act's impact on transplantation rates among elderly MEDICARE beneficiaries with end-stage renal disease. Transplantation 2013;95:463-9. [PMID: 23314351 DOI: 10.1097/TP.0b013e3182774366] [Reference Citation Analysis]
242 Pai AB, Nielsen JC, Kausz A, Miller P, Owen JS. Plasma pharmacokinetics of two consecutive doses of ferumoxytol in healthy subjects. Clin Pharmacol Ther 2010;88:237-42. [PMID: 20592725 DOI: 10.1038/clpt.2010.80] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
243 Chuengsaman P, Narenpitak S, Sritippayawan S. Efficacy and safety of recombinant human erythropoietin (Hema-Plus®) for management of anemia in Thai patients on peritoneal dialysis. World J Nephrol 2021; 10(6): 109-121 [PMID: 34909408 DOI: 10.5527/wjn.v10.i6.109] [Reference Citation Analysis]
244 Kapoian T, O’Mara NB, Singh AK, Moran J, Rizkala AR, Geronemus R, Kopelman RC, Dahl NV, Coyne DW. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008;19:372-379. [PMID: 18216316 DOI: 10.1681/asn.2007050606] [Cited by in Crossref: 128] [Cited by in F6Publishing: 43] [Article Influence: 9.1] [Reference Citation Analysis]
245 Auerbach M, Goodnough LT, Picard D, Maniatis A. The role of intravenous iron in anemia management and transfusion avoidance. Transfusion 2008;48:988-1000. [PMID: 18346021 DOI: 10.1111/j.1537-2995.2007.01633.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 16] [Article Influence: 0.2] [Reference Citation Analysis]
246 Kyle UG, Akcan-Arikan A, Orellana RA, Coss-Bu JA. Nutrition support among critically ill children with AKI. Clin J Am Soc Nephrol 2013;8:568-74. [PMID: 23293125 DOI: 10.2215/CJN.05790612] [Cited by in Crossref: 30] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
247 Cappell KA, Shreay S, Cao Z, Varker HV, Paoli CJ, Gitlin M. Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels. BMC Nephrol 2014;15:116. [PMID: 25015348 DOI: 10.1186/1471-2369-15-116] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
248 Moreno López R, Sicilia Aladrén B, Gomollón García F. Use of agents stimulating erythropoiesis in digestive diseases. World J Gastroenterol 2009; 15(37): 4675-4685 [PMID: 19787831 DOI: 10.3748/wjg.15.4675] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
249 Seliger S, Fox KM, Gandra SR, Bradbury B, Hsu VD, Walker L, Chiou CF, Fink JC. Timing of erythropoiesis-stimulating agent initiation and adverse outcomes in nondialysis CKD: a propensity-matched observational study. Clin J Am Soc Nephrol. 2010;5:882-888. [PMID: 20299377 DOI: 10.2215/cjn.07171009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
250 Townsend RR. Stroke in chronic kidney disease: prevention and management. Clin J Am Soc Nephrol 2008;3 Suppl 1:S11-6. [PMID: 18178791 DOI: 10.2215/CJN.03260807] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
251 Wu C, Chen X. Association of Serum Nonesterified Fatty Acids with Cardiovascular Event in Patients with Chronic Kidney Disease. Int J Gen Med 2021;14:2033-40. [PMID: 34079342 DOI: 10.2147/IJGM.S309595] [Reference Citation Analysis]
252 Czaya B, Faul C. The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia. Int J Mol Sci 2019;20:E4195. [PMID: 31461904 DOI: 10.3390/ijms20174195] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
253 Dowling TC. Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: an overview. Am J Health Syst Pharm 2007;64:S3-7; quiz S23-5. [PMID: 17591994 DOI: 10.2146/ajhp070181] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
254 El Shinnawy H, Khedr AR, Alghitany A, Ramzy M, Baki AH. Role of Intravenous Ascorbic Acid in the Management of Anemia in Hemodialysis Patients. Indian J Nephrol 2021;31:230-4. [PMID: 34376935 DOI: 10.4103/ijn.IJN_356_19] [Reference Citation Analysis]
255 De Nicola L, Chiodini P, Zoccali C, Borrelli S, Cianciaruso B, Di Iorio B, Santoro D, Giancaspro V, Abaterusso C, Gallo C, Conte G, Minutolo R; SIN-TABLE CKD Study Group. Prognosis of CKD patients receiving outpatient nephrology care in Italy. Clin J Am Soc Nephrol 2011;6:2421-8. [PMID: 21817127 DOI: 10.2215/CJN.01180211] [Cited by in Crossref: 68] [Cited by in F6Publishing: 38] [Article Influence: 6.2] [Reference Citation Analysis]
256 Lee SH, Kim M, Han KD, Lee JH. Low hemoglobin levels and an increased risk of psoriasis in patients with chronic kidney disease. Sci Rep 2021;11:14741. [PMID: 34285267 DOI: 10.1038/s41598-021-94165-w] [Reference Citation Analysis]
257 D’onofrio G, Simeoni M, Rizza P, Caroleo M, Capria M, Mazzitello G, Sacco T, Mazzuca E, Panzino MT, Cerantonio A, Segura-garcia C, Andreucci M, De Fazio P, Fuiano G. Quality of life, clinical outcome, personality and coping in chronic hemodialysis patients. Renal Failure 2017;39:45-53. [DOI: 10.1080/0886022x.2016.1244077] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 4.2] [Reference Citation Analysis]
258 Maruyama Y, Yokoyama K, Yokoo T, Shigematsu T, Iseki K, Tsubakihara Y. The Different Association between Serum Ferritin and Mortality in Hemodialysis and Peritoneal Dialysis Patients Using Japanese Nationwide Dialysis Registry. PLoS One 2015;10:e0143430. [PMID: 26599216 DOI: 10.1371/journal.pone.0143430] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
259 Amerling R, Winchester JF, Ronco C. Guidelines Have Done More Harm than Good. Blood Purif 2008;26:73-6. [DOI: 10.1159/000110569] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
260 Lau BC, Ong KY, Yap CW, Vathsala A, How P. Predictors of anemia in a multi-ethnic chronic kidney disease population: a case-control study. Springerplus 2015;4:233. [PMID: 26155438 DOI: 10.1186/s40064-015-1001-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
261 Shoji T, Niihata K, Fukuma S, Fukuhara S, Akizawa T, Inaba M. Both low and high serum ferritin levels predict mortality risk in hemodialysis patients without inflammation. Clin Exp Nephrol 2017;21:685-93. [PMID: 27503345 DOI: 10.1007/s10157-016-1317-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
262 Nguyen TV. Comparison of serum ferritin and transferrin saturation values associated with two i.v. iron formulations in hemodialysis patients. American Journal of Health-System Pharmacy 2009;66:1101-4. [DOI: 10.2146/ajhp080220] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
263 Levin A, Hemmelgarn B, Culleton B, Tobe S, McFarlane P, Ruzicka M, Burns K, Manns B, White C, Madore F. Guidelines for the management of chronic kidney disease. CMAJ. 2008;179:1154-1162. [PMID: 19015566 DOI: 10.1503/cmaj.080351] [Cited by in Crossref: 199] [Cited by in F6Publishing: 179] [Article Influence: 15.3] [Reference Citation Analysis]
264 Panichi V, Rosati A, Bigazzi R, Paoletti S, Mantuano E, Beati S, Marchetti V, Bernabini G, Grazi G, Rizza GM, Migliori M, Giusti R, Lippi A, Casani A, Barsotti G, Tetta C; RISCAVID Study Group. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol Dial Transplant. 2011;26:2641-2648. [PMID: 21325348 DOI: 10.1093/ndt/gfq802] [Cited by in Crossref: 79] [Cited by in F6Publishing: 61] [Article Influence: 7.2] [Reference Citation Analysis]
265 Jo IY, Kim WJ, Park HC, Choi HY, Lee JE, Lee SM. Effect of Personalized Nutritional Counseling on the Nutritional Status of Hemodialysis Patients. Clin Nutr Res 2017;6:285-95. [PMID: 29124049 DOI: 10.7762/cnr.2017.6.4.285] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
266 Lucas GM, Ross MJ, Stock PG, Shlipak MG, Wyatt CM, Gupta SK, Atta MG, Wools-Kaloustian KK, Pham PA, Bruggeman LA, Lennox JL, Ray PE, Kalayjian RC;  HIV Medicine Association of the Infectious Diseases Society of America. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;59:e96-138. [PMID: 25234519 DOI: 10.1093/cid/ciu617] [Cited by in Crossref: 173] [Cited by in F6Publishing: 162] [Article Influence: 21.6] [Reference Citation Analysis]
267 Liu J, Tian J, Chaudhry M, Maxwell K, Yan Y, Wang X, Shah PT, Khawaja AA, Martin R, Robinette TJ, El-Hamdani A, Dodrill MW, Sodhi K, Drummond CA, Haller ST, Kennedy DJ, Abraham NG, Xie Z, Shapiro JI. Attenuation of Na/K-ATPase Mediated Oxidant Amplification with pNaKtide Ameliorates Experimental Uremic Cardiomyopathy. Sci Rep 2016;6:34592. [PMID: 27698370 DOI: 10.1038/srep34592] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
268 Lee YS, Kim SW. Bioreducible polymers for therapeutic gene delivery. J Control Release 2014;190:424-39. [PMID: 24746626 DOI: 10.1016/j.jconrel.2014.04.012] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 6.3] [Reference Citation Analysis]
269 de Menezes AF, Motta DRMS, de Carvalho FO, Santana-Santos E, de Andrade Júnior MP, Figueirôa MF, Farias MIT, Bastos KA. Restless Legs Syndrome in Dialysis Patients: Does the Dialysis Modality Influence Its Occurrence and Severity? Int J Nephrol 2018;2018:1414568. [PMID: 29682346 DOI: 10.1155/2018/1414568] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
270 Jablonski KL, Chonchol M. Recent advances in the management of hemodialysis patients: a focus on cardiovascular disease. F1000Prime Rep 2014;6:72. [PMID: 25165571 DOI: 10.12703/P6-72] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
271 Rottembourg JB, Kpade F, Tebibel F, Dansaert A, Chenuc G. Stable hemoglobin in hemodialysis patients: forest for the trees--a 12-week pilot observational study. BMC Nephrol 2013;14:243. [PMID: 24180578 DOI: 10.1186/1471-2369-14-243] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
272 Jalalzadeh M, Shekari E, Mirzamohammadi F, Ghadiani MH. Effect of short-term intravenous ascorbic acid on reducing ferritin in hemodialysis patients. Indian J Nephrol 2012;22:168-73. [PMID: 23087549 DOI: 10.4103/0971-4065.86407] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
273 Anderson J, Glynn LG, Newell J, Iglesias AA, Reddan D, Murphy AW. The impact of renal insufficiency and anaemia on survival in patients with cardiovascular disease: a cohort study. BMC Cardiovasc Disord 2009;9:51. [PMID: 19909540 DOI: 10.1186/1471-2261-9-51] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
274 Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int 2012;82:235-41. [PMID: 22437411 DOI: 10.1038/ki.2012.76] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 5.7] [Reference Citation Analysis]
275 Wong CJ, Moxey-Mims M, Jerry-Fluker J, Warady BA, Furth SL. CKiD (CKD in children) prospective cohort study: a review of current findings. Am J Kidney Dis 2012;60:1002-11. [PMID: 23022429 DOI: 10.1053/j.ajkd.2012.07.018] [Cited by in Crossref: 138] [Cited by in F6Publishing: 97] [Article Influence: 13.8] [Reference Citation Analysis]
276 Bernieh B, Abouchacra S, Boobes Y, Al Hakim MR, Nagelkerke N, Chaaban A, Ahmed M, Hussain Q, Jack HE, Abayechi F, Khan I, Gebran N. Comparison between short- and long-acting erythropoiesis-stimulating agents in hemodialysis patients: target hemoglobin, variability, and outcome. Int Urol Nephrol 2014;46:453-9. [PMID: 24448756 DOI: 10.1007/s11255-013-0640-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
277 Han SY, Oh SW, Hong JW, Yi SY, Noh JH, Lee HR, Kim DJ. Association of Estimated Glomerular Filtration Rate with Hemoglobin Level in Korean Adults: The 2010-2012 Korea National Health and Nutrition Examination Survey. PLoS One 2016;11:e0150029. [PMID: 27128634 DOI: 10.1371/journal.pone.0150029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
278 Hung PH, Yeh CC, Sung FC, Hsiao CY, Muo CH, Hung KY, Tsai KJ. Erythropoietin prevents dementia in hemodialysis patients: a nationwide population-based study. Aging (Albany NY) 2019;11:6941-50. [PMID: 31484803 DOI: 10.18632/aging.102227] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
279 van Stralen KJ, Krischock L, Schaefer F, Verrina E, Groothoff JW, Evans J, Heaf J, Ivanov D, Kostic M, Maringhini S, Podracká L, Printza N, Pundziene B, Reusz GS, Vondrak K, Jager KJ, Tizard EJ; ESPN/ERA-EDTA Registry. Prevalence and predictors of the sub-target Hb level in children on dialysis. Nephrol Dial Transplant 2012;27:3950-7. [PMID: 22740719 DOI: 10.1093/ndt/gfs178] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
280 Guan XZ, Wang LL, Pan X, Liu L, Sun XL, Zhang XJ, Wang DQ, Yu Y. Clinical Indications of Recombinant Human Erythropoietin in a Single Center: A 10-Year Retrospective Study. Front Pharmacol 2020;11:1110. [PMID: 32848738 DOI: 10.3389/fphar.2020.01110] [Reference Citation Analysis]
281 Plastina JCR, Obara VY, Barbosa DS, Morimoto HK, Reiche EMV, Graciano A, Delfino VDA. Functional iron deficiency in patients on hemodialysis: prevalence, nutritional assessment, and biomarkers of oxidative stress and inflammation. J Bras Nefrol 2019;41:472-80. [PMID: 31441929 DOI: 10.1590/2175-8239-JBN-2018-0092] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
282 Susantitaphong P, Alqahtani F, Jaber BL. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis. Am J Nephrol 2014;39:130-41. [PMID: 24513913 DOI: 10.1159/000358336] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
283 Macdougall IC, Walker R, Provenzano R, de Alvaro F, Locay HR, Nader PC, Locatelli F, Dougherty FC, Beyer U; ARCTOS Study Investigators. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol 2008;3:337-47. [PMID: 18287255 DOI: 10.2215/CJN.00480107] [Cited by in Crossref: 68] [Cited by in F6Publishing: 27] [Article Influence: 4.9] [Reference Citation Analysis]
284 George C, Matsha TE, Korf M, Zemlin AE, Erasmus RT, Kengne AP. The agreement between fasting glucose and markers of chronic glycaemic exposure in individuals with and without chronic kidney disease: a cross-sectional study. BMC Nephrol 2020;21:32. [PMID: 32000712 DOI: 10.1186/s12882-020-1697-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
285 Gaweda AE, Nathanson BH, Jacobs AA, Aronoff GR, Germain MJ, Brier ME. Determining optimum hemoglobin sampling for anemia management from every-treatment data. Clin J Am Soc Nephrol 2010;5:1939-45. [PMID: 20671221 DOI: 10.2215/CJN.03540410] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
286 Neale J, Smith AC. Cardiovascular risk factors following renal transplant. World J Transplant 2015; 5(4): 183-195 [PMID: 26722646 DOI: 10.5500/wjt.v5.i4.183] [Cited by in CrossRef: 76] [Cited by in F6Publishing: 63] [Article Influence: 10.9] [Reference Citation Analysis]
287 Dounousi E, Mitsis M, Spanos G, Pappas C, Koutlas V, Tzalavra I, Xarisis C, Glantzounis G, Fatouros M, Siamopoulos KC. Assessment of nonimmunologic factors in kidney transplant recipients according to Kidney Disease Improving Global Outcomes. Transplant Proc 2012;44:2709-11. [PMID: 23146500 DOI: 10.1016/j.transproceed.2012.09.010] [Reference Citation Analysis]
288 Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, Ganz T, Rivera S, Nissenson AR, Salusky IB. Hepcidin--a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:1051-1056. [PMID: 19406957 DOI: 10.2215/cjn.05931108] [Cited by in Crossref: 200] [Cited by in F6Publishing: 97] [Article Influence: 15.4] [Reference Citation Analysis]
289 Lin KC, Tsai MY, Chi CL, Yu LK, Huang LH, Chen CA. Serum ferritin is associated with arterial stiffness in hemodialysis patients: results of a 3-year follow-up study. Int Urol Nephrol 2015;47:1847-53. [PMID: 26329743 DOI: 10.1007/s11255-015-1090-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
290 Okparavero A, Foster MC, Tighiouart H, Gudnason V, Indridason O, Gudmundsdottir H, Eiriksdottir G, Gudmundsson EF, Inker LA, Levey AS. Prevalence and complications of chronic kidney disease in a representative elderly population in Iceland. Nephrol Dial Transplant 2016;31:439-47. [PMID: 26519958 DOI: 10.1093/ndt/gfv370] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
291 Currin SD, Gondwe MS, Mayindi NB, Chipungu S, Khoza BL, Tollman S, Fabian J, George JA; ARK Consortium. Diagnostic accuracy of semiquantitative point of care urine albumin to creatinine ratio and urine dipstick analysis in a primary care resource limited setting in South Africa. BMC Nephrol 2021;22:103. [PMID: 33743616 DOI: 10.1186/s12882-021-02290-5] [Reference Citation Analysis]
292 Kuwahara M, Arai Y, Takehara E, Sasaki Y, Yoshimine T, Kusaka K, Shikuma S, Akita W, Uchida S. Early response to erythropoiesis-stimulating agents in non-dialysis chronic kidney disease patients. Clin Exp Nephrol 2016;20:585-94. [PMID: 26511877 DOI: 10.1007/s10157-015-1188-x] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
293 Hou Y, Li X, Yang L, Liu C, Wu H, Xu Y, Yang F, Du Y. Factors associated with depression and anxiety in patients with end-stage renal disease receiving maintenance hemodialysis. Int Urol Nephrol 2014;46:1645-9. [PMID: 24619584 DOI: 10.1007/s11255-014-0685-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
294 Raundhal M, Ghosh S, Myers SA, Cuoco MS, Singer M, Carr SA, Waikar SS, Bonventre JV, Ritz J, Stone RM, Steensma DP, Regev A, Glimcher LH. Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias. Nat Immunol 2021;22:520-9. [PMID: 33753942 DOI: 10.1038/s41590-021-00895-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
295 Van Wyck D, Eckardt K, Uhlig K, Rocco M, Levin A. Appraisal of Evidence and Control of Bias in the Kidney Disease Outcomes Quality Initiative Guideline Development Process. CJASN 2006;2:8-10. [DOI: 10.2215/cjn.02840806] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
296 Kim T, Rhee CM, Streja E, Obi Y, Brunelli SM, Kovesdy CP, Kalantar-Zadeh K. Longitudinal trends in serum ferritin levels and associated factors in a national incident hemodialysis cohort. Nephrol Dial Transplant 2017;32:370-7. [PMID: 28186572 DOI: 10.1093/ndt/gfw012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
297 Xie Y, Jia Y, Cuihua X, Hu F, Xue M, Xue Y. Urinary Exosomal MicroRNA Profiling in Incipient Type 2 Diabetic Kidney Disease. J Diabetes Res 2017;2017:6978984. [PMID: 29038788 DOI: 10.1155/2017/6978984] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 8.8] [Reference Citation Analysis]
298 Locatelli F, Altieri P, Andrulli S, Sau G, Bolasco P, Pedrini LA, Basile C, David S, Feriani M, Nebiolo PE, Ferrara R, Casu D, Logias F, Tarchini R, Cadinu F, Passaghe M, Fundoni G, Villa G, Di Iorio BR, Zoccali C. Predictors of haemoglobin levels and resistance to erythropoiesis-stimulating agents in patients treated with low-flux haemodialysis, haemofiltration and haemodiafiltration: results of a multicentre randomized and controlled trial. Nephrol Dial Transplant 2012;27:3594-600. [PMID: 22622452 DOI: 10.1093/ndt/gfs117] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
299 Portales-castillo I, Kroshinsky D, Malhotra CK, Culber-costley R, Cozzolino MG, Karparis S, Halasz CL, Goverman J, Manley HJ, Malhotra R, Nigwekar SU. Calciphylaxis-as a drug induced adverse event. Expert Opinion on Drug Safety 2019;18:29-35. [DOI: 10.1080/14740338.2019.1559813] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
300 Mould DR, Frame B. Population pharmacokinetic-pharmacodynamic modeling of biological agents: when modeling meets reality. J Clin Pharmacol. 2010;50:91S-100S. [PMID: 20881222 DOI: 10.1177/0091270010376965] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
301 Foley RN. Erythropoietin: physiology and molecular mechanisms. Heart Fail Rev 2008;13:405-14. [PMID: 18236154 DOI: 10.1007/s10741-008-9083-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
302 Vandevoorde RG, Warady BA. Management of Chronic Kidney Disease. In: Avner E, Harmon W, Niaudet P, Yoshikawa N, editors. Pediatric Nephrology. Berlin: Springer Berlin Heidelberg; 2009. pp. 1661-92. [DOI: 10.1007/978-3-540-76341-3_68] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
303 Assunção J, Vinhas J. Antibody-mediated pure red cell aplasia (PRCA) on switching from darbepoetin alfa to epoetin beta: what are the implications? NDT Plus 2008;1:230-2. [PMID: 25983889 DOI: 10.1093/ndtplus/sfn064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
304 Wald R, Yan AT, Perl J, Jiang D, Donnelly MS, Leong-Poi H, McFarlane PA, Weinstein JJ, Goldstein MB. Regression of left ventricular mass following conversion from conventional hemodialysis to thrice weekly in-centre nocturnal hemodialysis. BMC Nephrol 2012;13:3. [PMID: 22260388 DOI: 10.1186/1471-2369-13-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
305 Lien C, Tsai C, Chen C, Kuo C, Tsai M. Serum ferritin is an independent factor in coronary artery stenosis among hemodialysis patients. Int J Hematol 2016;104:440-5. [DOI: 10.1007/s12185-016-2045-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
306 Maekawa K, Shoji T, Emoto M, Okuno S, Yamakawa T, Ishimura E, Inaba M, Nishizawa Y. Influence of atherosclerosis on the relationship between anaemia and mortality risk in haemodialysis patients. Nephrology Dialysis Transplantation 2008;23:2329-36. [DOI: 10.1093/ndt/gfm929] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
307 Wu IW, Hsu KH, Lee CC, Sun CY, Hsu HJ, Hung MJ, Wu MS. Re-evaluating the predictive roles of metabolic complications and clinical outcome according to eGFR levels--a four-years prospective cohort study in Taiwan. BMC Nephrol 2013;14:92. [PMID: 23607513 DOI: 10.1186/1471-2369-14-92] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
308 Mehrotra A, Tan JA, Ames SA. "Out of Sight, Out of Mind": The Failed Renal Allograft as a Cause of ESA Resistance. Semin Dial 2015;28:530-2. [PMID: 26096871 DOI: 10.1111/sdi.12401] [Reference Citation Analysis]
309 Yahata K, Seta K, Kikuchi Y, Koizumi M, Murata M, Wada H, Murakami S, Ohishi M, Tsuji H; Kyoto Fushimi Renal Anemia study investigators. Treatment for renal anemia and outcomes in non-dialysis patients with chronic kidney disease: the current status of regional medicine according to the Kyoto Fushimi Renal Anemia (KFRA) study. Clin Exp Nephrol 2019;23:1211-20. [PMID: 31342291 DOI: 10.1007/s10157-019-01767-w] [Reference Citation Analysis]
310 Ryu SR, Park SK, Jung JY, Kim YH, Oh YK, Yoo TH, Sung S. The Prevalence and Management of Anemia in Chronic Kidney Disease Patients: Result from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD). J Korean Med Sci 2017;32:249-56. [PMID: 28049235 DOI: 10.3346/jkms.2017.32.2.249] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
311 Butler SE, Muok EM, Montgomery SP, Odhiambo K, Mwinzi PM, Secor WE, Karanja DM. Mechanism of anemia in Schistosoma mansoni-infected school children in Western Kenya. Am J Trop Med Hyg 2012;87:862-7. [PMID: 22987658 DOI: 10.4269/ajtmh.2012.12-0248] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
312 Ketteler M, Wüthrich RP, Floege J. Management of hyperphosphataemia in chronic kidney disease-challenges and solutions. Clin Kidney J 2013;6:128-36. [PMID: 26019840 DOI: 10.1093/ckj/sfs173] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
313 Hayat A, Haria D, Salifu MO. Erythropoietin stimulating agents in the management of anemia of chronic kidney disease. Patient Prefer Adherence 2008;2:195-200. [PMID: 19920963 DOI: 10.2147/ppa.s2356] [Cited by in Crossref: 5] [Cited by in F6Publishing: 14] [Article Influence: 0.4] [Reference Citation Analysis]
314 Gonzalez-campoy JM, Castorino K, Ebrahim A, Hurley D, Jovanovic L, Mechanick JI, Petak SM, Yu Y, St. Jeor ST, Harris KA, Kris-etherton P, Kushner R, Molini-blandford M, Nguyen QT, Plodkowski R, Sarwer DB, Thomas KT, Bailey TS, Bloomgarden ZT, Braverman L, Brett EM, Caldarella FA, Camacho P, Cheskin LJ, Dagogo-jack S, Dodell G, Einhorn D, Garber A, Garvey T, Gharib H, Grunberger G, Haas RA, Handelsman Y, Harrell RM, Lando HM, Levine MJ, Licata A, Mcgill JB, Mcmahon M, Pearce E, Pessah-pollack R, Rettinger H, Ryan D, Shambaugh GE, Tangpricha V, Thomas A, Torre J, Weber S, Weiss D. Clinical Practice Guidelines for Healthy Eating for the Prevention and Treatment of Metabolic and Endocrine Diseases in Adults: Cosponsored by the American Association of Clinical Endocrinologists/The American College of Endocrinology and the Obesity Society. Endocrine Practice 2013;19:1-82. [DOI: 10.4158/ep13155.gl] [Cited by in Crossref: 59] [Cited by in F6Publishing: 22] [Article Influence: 6.6] [Reference Citation Analysis]
315 Picon PD, Pribbernow SC, Prompt CA, Schacher SC, Antunes VV, Mentz BP, Oliveira FL, Souza CM, Schacher FC. Randomized double-blind clinical trial of a new human epoetin versus a commercially available formula for anemia control in patients on hemodialysis. Clinics (Sao Paulo) 2014;69:547-53. [PMID: 25141114 DOI: 10.6061/clinics/2014(08)08] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
316 Sánchez-fructuoso AI, Ruiz JC, Torregrosa JV, González E, Gómez E, Gallego RJ, Troya MI, Jimenez C, Llamas F, Romero R, Bernis C, Crespo JF, Guirado L. Anemia Control in Renal Transplant Recipients Receiving Continuous Erythropoietin Receptor Activator (C.E.R.A.) Treatment: The AnemiaTrans Study. Adv Therapy 2012;29:979-91. [DOI: 10.1007/s12325-012-0063-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
317 Crugliano G, Serra R, Ielapi N, Battaglia Y, Coppolino G, Bolignano D, Bracale UM, Pisani A, Faga T, Michael A, Provenzano M, Andreucci M. Hypoxia-Inducible Factor Stabilizers in End Stage Kidney Disease: "Can the Promise Be Kept?". Int J Mol Sci 2021;22:12590. [PMID: 34830468 DOI: 10.3390/ijms222212590] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]